

Molecular Mechanism of Active Cas7-11 in Processing CRISPR RNA and Interfering Target RNA

Hemant Gowswami¹, Jay Rai¹, Anuska Das¹, and Hong Li^{1,2*}

¹Institute of Molecular Biophysics, Florida State University, Florida State University,
Tallahassee, FL, USA

²Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL 32306,
USA.

Corresponding author: hong.li@fsu.edu

Abstract

Cas7-11 is a Type III-E CRISPR Cas effector that confers programmable RNA cleavage and has potential applications in RNA interference. Cas7-11 encodes a single polypeptide containing four Cas7- and one Cas11-like segments that obscures the distinction between the multi-subunit Class 1 and the single-subunit Class-2 CRISPR-Cas systems. We report a cryo-EM structure of the active Cas7-11 from *Desulfonema ishimotonii* (DiCas7-11) that reveals the molecular basis for RNA processing and interference activities. DiCas7-11 arranges its Cas7- and Cas11-like domains in an extended form that resembles the backbone made up by four Cas7 and one Cas11 subunits in the multi-subunit enzymes. Unlike the multi-subunit enzymes, however, the backbone of DiCas7-11 contains evolutionarily different Cas7 and Cas11 domains, giving rise to their unique functionality. The first Cas7-like domain nearly engulfs the last 15 direct repeat nucleotides and is responsible for processing and recognition of the CRISPR RNA. Whereas both the second and the third Cas7-like domains mediate target RNA cleavage, they differ in metal requirement for catalysis. The long variable insertion to the fourth Cas7-like domain has little impact to RNA processing or targeting, suggesting the possibility for engineering a compact and programmable RNA interference tool.

One Sentence Summary Structures of Cas7-11 reveal the molecular basis for processing CRISPR RNA and for cleaving target RNA.

Main Text

The CRISPR-Cas systems confer adaptive immunity to prokaryotic hosts against invading viruses by encoding a range of different CRISPR-Cas efforts that interfere with the invader nucleic acids¹. Three types of CRISPR-Cas effectors are known to utilize programmable CRISPR RNA (crRNA) to guide cleavage of the complementary target RNA. The multi-subunit Type III effectors, exemplified by the Type III-A (Csm) and the III-B subtypes (Cmr), assemble 4-5 Cas7, 2-3 Cas11, and 1 Cas10 subunits into a sea horse-shaped helical enzyme². They cleave the target RNA at a 6-nucleotide (nt) interval within the complementary region that coincides with the evenly spaced Cas7 subunits³⁻⁵. The Type VI, or Cas13, is a single subunit and substantially smaller effector. Unlike Csm/Cmr, Cas13 employs two Higher Prokaryotic and Eukaryotic binding domains (HEPN) in cleaving the target RNA outside the complementary region^{6,7}. The recently discovered Type III-E effector, Cas7-11 or gRAMP (for giant Repeat Associated Mysterious Protein), is also a single subunit effector with fused Cas7 and Cas11 segments^{8,9} (Figure 1a). Unlike Cas13 but similar to Csm/Cmr, Cas7-11 employs the Cas7-like segments to cleave crRNA-guided target RNA (Figure 1a). Interestingly, whereas Cas13 can distinguish self from foreign RNA by utilizing the 3' protospacer flanking sequence (PFS) in the target RNA¹⁰, both Csm/Cmr and Cas7-11 are insensitive to 3' PFS in cleaving their respective target RNA^{8,9}. The three effectors also differ in crRNA processing. Csm/Cmr utilize an independent processing endonuclease, Cas6, to result in a mature crRNA containing an 8-nucleotide (nt) repeat (5'-tag) linked to the spacer¹¹. By contrast, both Cas13 and Cas7-11 process their own crRNA⁷⁻⁹. Cas7-11 is therefore believed to be an evolutionary intermediate between the Class 1 and 2 effectors. Interestingly, Cas7-11 has been demonstrated form a complex with the caspase-like TPR-CHAT peptidase, suggesting a potential

for a viral RNA-induced and protease-mediated antiviral immunity⁸. Given the known collateral nuclease activities of Cas13^{6,7} and Csm/Cmr^{3,4,12}, and the complex enzyme composition of Csm/Cmr, Cas7-11 provides a desirable platform to further develop RNA interference and editing tools. To understand the molecular basis for crRNA processing and target interference of Cas7-11, we determined a cryo-electron microscopy (cryo-EM) structure of *Desulfonema ishimotonii* Cas7-11 (DiCas7-11) at an overall resolution of 2.82 Å (Figure 1b-1c, Supplementary Figure 1, Supplementary Figure 1 & Supplementary Table 1). DiCas7-11 has been demonstrated to function in programmable RNA cleavage and editing both in vitro and in mammalian cells^{8,9}. Our structure provides the architecture of the enzyme and the molecular basis for its enzymatic activities.

The wild-type DiCas7-11 was incubated with its precursor crRNA and a complementary target RNA under a reactive condition before being made frozen specimen (Supplementary Figure 1). Under this condition, DiCas7-11 successfully processes the precursor crRNA and cleaves the target RNA (Supplementary Figure 1). The density map resolves most of the DiCas7-11 protein, the crRNA and the partially cleaved target RNA (Figure 1b-1c, Supplementary Figure 2 & Supplementary Figure 3). The core Cas7-11 assembly is half-moon shaped with four Cas7-like (C7L) domains (C7L.1 – C7L.4 from N- to the C-terminus) forming a long ridge and a single Cas11-like domain (C11L) occupying the crescent center. The entire DiCas7-11 complex can be superimposed onto the closely matched homologous *Lactococcus lactis* Csm (LICsm) complex¹³ with the C7L.1-C7L.4 ridge matching that formed by four Csm3 subunits and C11L matching the Csm2 subunit adjacent to Cas10 (Supplementary Figure 4). The similarity in the bound RNA trajectory at the core between the two complex is striking (Supplementary Figure 4), suggesting a similar RNA binding apparatus in both complexes. DiCas7-11 lacks the domains equivalent to the

Csm4 and the Csm1 subunits and, thus, the functions associated with them. In Csm complexes, Csm4 recognizes and stabilizes the 8-nt 5'-tag derived from the direct repeat whereas Csm1 carries out cyclic oligoadenylate synthesis and ancillary DNA cleavage¹³⁻¹⁵. Csm1 also secures the 3'-PFS of the cognate target RNA, and thus, plays a role in discrimination of self from foreign RNA¹³⁻¹⁵.

Despite the overall structural similarity between the C7L- and the LICsm-formed ridge (Supplementary Figure 4 & Supplementary Figure 5), each C7L differs slightly in protein sequence and folding (Supplementary Figure 4b), which gives rise to their different roles in binding and cleaving RNA. The 34-nt crRNA lies along the C7L-ridge with its 5' tag spanning C7L.1-C7L.2 and the spacer region covering C7L.3-C7L.4 (Figure 1b-1c & Supplementary Figure 3). The first 18 nucleotides of the target RNA (+19* ~ +2*) remain base paired with the spacer region of the crRNA (Figure 1c, Supplementary Figure 3, & Supplementary Figure 5). The short span of the guide-target region on C7L domains explains the two, instead of four as in Csm, sites of target cleavage^{8,9}.

The observed structure suggests that the precursor crRNA (pre-crRNA) is processed by the first C7L domain, which yields a mature crRNA containing the last 15 nucleotides of the direct repeat linked to the programmed spacer (Figure 1c, Figure 2a, & Supplementary Figure 3). To confirm the site of processing, we subjected synthetic pre-crRNA containing 2'-deoxy modification at -16, -15, or -14 position to the processing reaction, respectively, and found that the cleavage products are consistent with the density-derived 15-nt 5'-tag (Figure 2b & Supplementary Figure 3). Strikingly, the sequence identity downstream of U(-15) is not important for processing,

as those substituted with poly-adenine or the previously characterized *Candidatus Scalindua broadae* (Csb) pre-crRNA are successfully processed by DiCas7-11 (Figure 2c). A well conserved histidine residue, His43, is immediately next to the leaving 5'-hydroxyl oxygen of the -15 nucleotide, suggesting its role in processing. Consistently, His43 to alanine mutation (H43A) abolished pre-crRNA cleavage (Figure 2c). The requirement for His43 with no divalent metals in processing suggests that the C7L.1 employs a RNase A-like mechanism similar to that suggested for Cas6^{16,17}. Interestingly, CsbCas7-11 contains threonine in place of histidine and does not process its crRNA at position -15⁸, suggesting that precise processing may not be required for the RNA interference activity.

The processed 15-nt 5'-tag interacts extensively with C7L.1 and to less extend with C7L.2 (Figure 2a & Supplementary Figure 5). The protein nearly buries the entire 5'-tag and thus precluded it from further base pairing with a complementary RNA. The C7L.1 forms a ferredoxin fold ($\beta 2 \uparrow \beta 3 \downarrow \alpha 2 \beta 1 \uparrow \alpha 1 \beta 4 \downarrow$) highly abundant in CRISPR-Cas components^{18,19}. It uses $\alpha 1$, $\beta 2$, a long β -hairpin connecting $\beta 2$ to $\beta 3$ (thumb) and a C7L.1-specific insertion loop (finger) to secure the significantly bent 5'-tag, resembling a rope-gripping right hand (Figure 2a & Supplementary Figure 5). The first nucleotide, U(-15), forms a hydrogen bond network with a number of residues including the well conserved His43 (Figure 2a & Supplementary Figure 5). Removal of U(-15) did not impact target RNA cleavage (Figure 2d), suggesting the possibility that the U(-15)-protein interactions may be important for processing rather than target interference. The most extensive interactions take place at the strictly conserved A(-12)-U(-11)-G(-10)-U(-9) tetranucleotide. Both sidechain as well as mainchain atoms of C7L.1 participate in "reading" the four RNA bases. Strikingly, all edges of G(-10), the Watson-Crick, the Hoogsteen, and the Sugar, are in close

contacts with the C7L.1 residues (Figure 2a). Downstream of the AUGU tetranucleotide is a tight right-handed helical turn formed by C(-8)-A(-7)-C(-6)-G(-5), reminiscent the 3_{10} helix in proteins. The turn is stabilized by both base stacking as well as an unusual network of intra-strand polar contacts. The base of G(-5) interdigitates those of C(-8) and A(-7) with Arg35 on top, leaving C(-6) protruding into the interior of the protein (Figure 2a). Whereas phosphate backbone atoms in A-form RNA do not engage in intra-strand contacts, those within the turn mediate numerous interactions (Figure 2a). The strictly conserved G(-5) forms the most intra-strand interactions. Its N2 atom contacts the non-bridging oxygen of A(-7) while its non-bridging oxygen forms hydrogen bond with 2'-OH of C(-8). Finally, the 2'-OH of G(-5) forms bifurcated contacts with the N7 atom of the strictly conserved A(-7) and G(-4). The rest of the 5'-tag is clamped down by the thumb of C7L.1 and $\alpha 1$ of C7L.2 analogously as by two Cas7 subunits in Csm complexes¹³. Consistent with the extensive 5'-tag-protein interactions, removal of either first 4 or 8 5'-tag nucleotides abolished RNA-guided target cleavage (Figure 2d).

The spacer region of the crRNA is captured by the rest of the C7L ridge and base paired with the target RNA (Figure 3a). Three of the four C7L domains contain the characteristic “thumb” that secure the crRNA at two evenly spaced (6-nt) kinks with bases flipped. The duplex bound by C7L.4 creates an extra spacing between the G(+13*)-C(+13) and G(+14*)-C(+14) pairs but no base flipping. Like the multi-subunit Type III efforts, the kinked crRNA-target RNA duplex create bended sugar-phosphate backbone at the locations that coincide with the sites of cleavage. Consistently, the target RNA containing 2'-deoxy modification at A(+4*) (site 1) and C (+10*) (site 2) prevented formation of any cleavage product (Figures 3b & 3c). Two acidic residues, Asp429 and Asp654, were previously shown to be critical to cleavage at site 1 and site 2,

respectively ⁹. Satisfactorily, they are found near each corresponding scissile phosphate with the carboxylate oxygen 4.2-6.7 Å from the leaving 5'-oxygen (Figure 3a). At both sites, the phosphodiester bond breakage is further assisted by the near “in-line” geometry of the nucleophilic 2'-oxygen, the scissile phosphate and the leaving 5'-oxygen (Figure 3a). Two residues from the C11L domain, Arg283 (site 1) and His306 (site 2), where Arg283 is better conserved than His306, are observed to stabilize the attacking nucleotides by stacking on their bases (Figure 3a).

Interestingly in the homologous CsbCas7-11, Asp429 is not conserved and mutation of its equivalent Asp448 and other surrounding residues did not impact site 1 cleavage ⁸. We observed that, unlike cleavage at site 2 that strictly depends on Mg²⁺, cleavage at site 1 is independent of metal ions (Figures 2d, 3b & 3d), similar to its own processing activity or that by crRNA processing endonuclease Cas6 ^{16,17}. In Cas6, multiple amino acids are observed to fulfil the catalytic roles and therefore, the RNA geometry is believed to play a critical role in catalysis. It is thus possible that a correct RNA geometry at site 1, shaped by the protein, significantly accelerates catalysis. To access possible roles of other residues near site 1 in catalysis, we mutated the well conserved Tyr360 of C2L given its proximity to A23 (Figure 3a). Surprisingly, we found that Tyr360 is not required for site 1 cleavage (Figure 3b & 3f), indicating that, at least for DiCas7-11, Asp429 is sufficient for mediating the metal-dependent cleavage.

To access the length of base pairing required for target cleavage, we further examined the cleavage of a series of truncated target from either the 3' or the 5' end. We found that as short of 16 base pair in total length and 2 base pairs on one flanking end can facilitate RNA cleavage

(Figures 3b & 3e), suggesting that protein and crRNA plays a significant role in shaping the target RNA for cleavage.

Though the final atomic model of DiCas7-11 lacks the large insertion to C7L.4 (residues 979-1297) due to weak density, focused classification and refinement led to a low-resolution map that matches the AlphaFold-predicted model of the insertion domain (Figure 4a & 4b). This model indicates that a large majority of the insertion domain is not engaged with any of the features described above and suggests the possibility that it is not essential to RNA-guided target cleavage. To test this hypothesis, we removed residues 1009-1220 to create DiCas7-11- Δ int1. Consistently, we showed that DiCas7-11- Δ int1 retains almost all RNA-guided target cleavage in an in vitro assay (Figure 4c).

The structure and complementary biochemical assays show that Cas7-11 has a minimal architecture required for programmable RNA cleavage. The covalent linkage of the homologous units suggests an evolutionary advantage in dedicating Cas7-11 to RNA cleavage. Considering the known collateral RNase activity of Cas13 and the complicated Csm/Cmr systems, Cas7-11 offers a desirable alternative in developing gene regulation tools. While DiCas7-11 has been successfully demonstrated to function in mammalian cells, the efficiency and accuracy remain to be improved. With now the available structure and the accurately mapped processing and target cleavage sites, protein engineering may assist the efforts in designing improved Cas7-11-derived RNA interference platforms. DiCas7-1- Δ int1 provides a proof-of-concept for such an effort.

Methods and Materials

Protein expression and purification

Escherichia coli NiCo21 (DE3) competent cells were transformed with the plasmid encoding sumo-tag fused DiCas7-11 (Addgene: 172503). A single colony was picked and transferred to 100mL LB media containing 50 µg/mL ampicillin and grown for 12 hours at 37°C before inoculation into 1L LB culture. The cells were induced at mid-log phase with the addition of 0.5mM IPTG (isopropyl-β-D- thiogalactopyranoside) and grown overnight at 16°C and harvested. Cells were lysed and centrifuged at 4000rpm for 30 minutes in buffer A (20mM Tris pH 8.0, 500mM NaCl, 5mM β-mercaptoethanol and 5% glycerol) sonicated 10 times on pulse for 20 s with 40 s rest between the pulses. The cell lysate was centrifuged at 16000 rpm for 1 hour at 4°C and the resulting supernatant was passed through the pre-equilibrated Ni-NTA resin column. The protein bound resins were washed by 100mL buffer B (20mM Tris pH 8.0, 500mM NaCl, 5mM β-mercaptoethanol, 5% glycerol and 50mM imidazole) and eluted with buffer C (20mM Tris pH 8.0, 500mM NaCl, 5mM β-mercaptoethanol, 5% glycerol and 300mM imidazole). The ULP1 protease was added to the elutant to remove the sumo-tag from DiCas7-11 while dialyzing at 4°C overnight. The digested protein solution was diluted 2-fold before being loaded onto a heparin column pre-equilibrated with buffer D (20mM Tris pH 8.0, 250mM NaCl, 5mM β-mercaptoethanol and 5% glycerol). The bound protein was eluted with a salt gradient. Pooled fractions were further purified on a gel filtration column in buffer E (20mM Tris pH 8.0, 500mM NaCl, 2mM DTT and 5% glycerol). The protein containing fractions were pooled, concentrated to 21mg/mL, aliquoted and stored at -80 °C for future use. The DiCas7-11 mutants were prepared by

Q5 2X master mix mutagenesis kit (New England Biolabs) using primers listed in Supplementary Table 2 and purified similarly as the wild-type DiCas7-11.

In vitro transcription and purification

For synthesis of 59nt pre-crRNA, DNA oligonucleotides appended with T7 promoter sequence were ordered from Eurofins (Supplementary Table 2). The complementary oligos, 50µM in concentration, were annealed at 95°C followed by gradual cooling to 25°C at 1°C per minute rate. Next, 2.5µL of annealing reaction was mixed with a transcription reaction master-mix (50 mM Tris pH 8.0, 10 mM DTT 20 mM MgCl₂, 0.5 mM NTPs, and 48 µg/mL T7 RNA polymerase in a 50µL reaction. The in-vitro transcription reaction was kept overnight at 37°C and treated with 2U of Turbo DNase (Invitrogen) for 1 hour at 37°C. The final product was purified by Monarch RNA Cleanup kit (New England Biolabs), eluted in water, flash frozen using liquid nitrogen and stored at -80 °C.

RNA target cleavage

The in-vitro target RNA cleavage assays were performed in a cleavage buffer containing 40 mM Tris pH 8.0, 70mM sodium chloride, 10 mM MgCl₂. A binary complex was first prepared by incubating 400nM Cas7-11 with 500nM crRNA for 30 min at 37 °C. The resulting samples were then incubated with 500nM target RNA (5Cy3 labelled or non-labelled) for 1h at 37 °C. The reactions were stopped by using 2x formamide dye (95% formamide, 0.025% SDS, 0.025% xylene cyanol FF, 0.5 mM EDTA). The samples were heated at 95 °C for 5 min and separated by 8 M Urea, 12% polyacrylamide-gel electrophoresis (PAGE) gels in 1x Tris Borate EDTA (TBE)

running buffer and were visualized by staining with SYBR Gold II (Invitrogen) stain or fluorescence imager.

Pre-crRNA processing

500nM of DiCas7-11 was incubated with 500nM of pre-crRNA at 37°C for 30 min in a 15 µL reactions containing 1X processing buffer (40 mM Tris, pH 8.0, 70 mM NaCl). The reactions were stopped by using 2x formamide dye (95% formamide, 0.025% SDS, 0.025% xylene cyanol FF, 0.5 mM EDTA). The samples were heated at 95 °C for 5 min and separated by 8 M Urea, 12% polyacrylamide-gel electrophoresis (PAGE) gels in 1x TBE running buffer and were visualized by staining with SYBR Gold II (Invitrogen) stain or fluorescence imager.

Sample preparation and data collection for cryo-EM studies

To reconstitute the ternary complex, 400µg wild-type DiCas7-11 protein was incubated with 1.5 molar excess of a pre-crRNA in the buffer (30mM Tris pH 8.0, 60mM NaCl) at 37°C for 45 minutes followed by separation on a Superdex 200 increase 10/300 gel filtration column in the buffer (30mM HEPES pH 7.5, 180mM NaCl, 10mM MgCl₂ and 2mM TCEP). The peak fraction at 0.3mg/mL determined by UV 280nm absorbance was collected and further incubated with 2 molar excess target RNA at 37°C for 10 minutes before grid preparation. The Cas7-11-crRNA-target-RNA sample in 5µL volume was added onto glow-discharged 300 mesh Cu R1.2/1.3 holey carbon grids (Quantifoil) with extra layer of carbon (2 nm), blotted for 3s at 100% humidity using

FEI Vitrobot Mark IV. After flash-freezing in liquid ethane, the grids were transferred to liquid nitrogen for storage until cryo-EM imaging.

The Cas7-11 ternary complex micrographs were collected using EPU software on the Krios G3i cryo TEM (ThermoFisher Scientific) equipped with Gatan Bioquantum K3 direct electron detector (Gatan) with 15 eV energy filter in a counted super-resolution mode. All 4177 images were collected at a dose rate of 60 e-/Å² with 1e-/Å² per frame in a pixel size of 0.825 Å/pixel. Motion correction was performed in bin 2 using MotionCorr 2²⁰ in a wrapper provided in Relion 4.0²¹ and contrast transfer function (CTF) parameters were estimated with Gctf²² implemented in cryo-SPARC²³. The stack was generated and imported to cryoSPARC for particle picking and 2D classification. The images with bad ice, astigmatism, drift, and poor sample quality were rejected resulting in 4168 images for further processing and particle picking, which resulted in a total of 1,301,452 particles. Several rounds of 2D classification led to 645,053 particles with good quality. RELION-4.0 was used to classify the particles, which led to further reduction of particles to 226,320 based on high-resolution features for reconstruction.

Model building and refinement

The DiCas7-11 protein was built from an AlphaFold²⁴ predicted structure model using the program COOT²⁵. The final DiCas7-11-crRNA-target RNA complex was refined in PHENIX²⁶ to satisfactory stereochemistry and density correlation parameters (Supplementary Table 1).

Figure legends

Figure 1. Structure overview of DiCas7-11-crRNA-target-RNA ternary complex. (a) Domain organization of DiCas7-11 and schematic representation of crRNA-target RNA duplexes used in the study. The blue and green colored triangles indicate the pre-crRNA processing and target RNA cleavage sites, respectively. C7L denotes Cas7-like domain and C11L denotes Cas11-like domain. (b) Top, electron potential density map of DiCas7-11-crRNA-target-RNA ternary complex shown in two different orientations. Bottom, cartoon representation of DiCas7-11-crRNA-target-RNA ternary complex shown the same views as in top panel with corresponding colors representing protein domains and the two RNA strands. (c) Close-up view of the density for the crRNA (spacer:black, repeat:light pink) and target RNA (red) duplex.

Figure 2. Precursor crRNA processing and recognition. (a) The mode of Cas7-like domain 1 (C7L.1) and C7L.2 interaction with the processed crRNA nucleotides -15 to -1 in both cartoon (Top) and surface (bottom) representations. Key secondary elements involved in crRNA interaction are labeled. Insets indicate close-up views around U(-15)-U(-13)-G(-13), the tight RNA turn, and the conserved A(-12)-U(-11)-G(-10)-U(-9) tetranucleotide. Dashed lines indicate close polar contacts. (b) RNA processing results analyzed on polyacrylamide urea gel with the wild-type and deoxy modified precursor crRNA (pre-crRNA) by DiCas7-11. The sites of deoxy modification are indicated by marked nucleotide positions on the wild-type pre-crRNA, respectively. The control RNA contains the last 14 nucleotides of the repeat plus the spacer. Pre-crRNA processing site is indicated by a blue triangle. (c) RNA processing results analyzed on polyacrylamide urea gel with the wild-type and the His43 to alanine mutant of DiCas7-11 with the wild-type, poly-adenine-substituted, and the *Candidatus Scalindua broadae* (Csb) pre-crRNA. (d) Target RNA

cleavage results analyzed on polyacrylamide urea gel with the wild-type and truncated precursor crRNA (pre-crRNA) by DiCas7-11 in the presence and absence of EDTA.

Figure 3. Target RNA cleavage mechanism. (a) Recognition of target RNA by the crRNA and DiCas7-11. The ferredoxin fold $\alpha 1$ and the thumb hairpin for each of the four Cas7-like (C7L) domains are shown as cartoons and colored as in Figure 1. “thumb” indicates the degenerate thumb feature for C7L4 domain. The sites of target cleavage are boxed and shown in close-up views, respectively. Residues and amino acids are shown in stick models. The three atoms involved in the phosphodiester bond breakage are labeled and the angles they form are indicated by thin dash lines. The closest of the three atoms to the putative catalytic residues, Asp654 (for site 2) and Asp429 (for site), are indicated by a connecting dash line. (b) Schematic of the labelled (*target) and non-labelled target RNA used to test DiCas7-11 cleavage activity. Asterisks mark the location of the deoxy modification on the target RNA (deoxy RNA). (c-f) Target RNA cleavage by DiCas7-11 and its Tyr360 to alanine mutant are analyzed on polyacrylamide urea gel. Location of the target RNA, crRNA, and cleaved target RNA products are marked. Asterisk in (f) indicates a possible nondenatured crRNA:target pair.

Figure 4. Engineering a compact DiCas7-11. (a) Schematic of domain organization of wild-type and an insertion deletion variant DiCas7-11- Δ int1. The region removed is colored in purple and numbered. (b) Cartoon representation of DiCas7-11 overlaying with density map resulted from focused classification using a mask around the insertion domain. The insertion structure model is

from AlphaFold prediction. The region removed is colored in purple and numbered. (c) Target RNA cleavage by DiCas7-11 and DiCas7-11- Δ int1 are analyzed on a polyacrylamide urea gel. The crRNA, target and the cleaved products are labeled.

Data Availability

The atomic coordinates and associated density maps have deposited at Protein Data Bank with accession codes 8D1V & EMD-27138.

Acknowledgments

This work was supported by NIH grant R01 GM101343 to H.L. The authors also acknowledge the use of instruments at the Biological Science Imaging Resource supported by Florida State University. The Titan was funded from NIH grant S10 RR025080. The BioQuantum/K3 was funded from NIH grant U24 GM116788. The Vitrobot Mk IV was funded from NIH grant S10 RR024564. The Solaris Plasma Cleaner was funded from NIH grant S10 RR024564. The DE-64 was funded from NIH grant U24 GM116788. The Laboratory for BioMolecular Structure (LBMS) is supported by the DOE Office of Biological and Environmental Research (KP160711).

Author Contributions

H.G. A.D. and H.L. designed the experiments. H.G. purified the samples with the assistance of A.D. H.G. and J.R. prepared cryoEM grids and collected data. J.R. did cryoEM analysis with the assistance of H.G. H.G. J. R. and H.L analyzed data, wrote and edited manuscript and figures with the assistance of A.D.

1

2 **Conflict of interest**

3 The authors declare that they have no conflict of interest.


4

References


1. Makarova, K.S. et al. An updated evolutionary classification of CRISPR-Cas systems. *Nat Rev Microbiol* **13**, 722-36 (2015).
2. Molina, R., Sofos, N. & Montoya, G. Structural basis of CRISPR-Cas Type III prokaryotic defence systems. *Curr Opin Struct Biol* **65**, 119-129 (2020).
3. Elmore, J.R. et al. Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system. *Genes Dev* **30**, 447-59 (2016).
4. Samai, P. et al. Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity. *Cell* **161**, 1164-74 (2015).
5. Tamulaitis, G. et al. Programmable RNA shredding by the type III-A CRISPR-Cas system of *Streptococcus thermophilus*. *Mol Cell* **56**, 506-17 (2014).
6. Abudayyeh, O.O. et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science* (2016).
7. East-Seletsky, A. et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. *Nature* **538**, 270-273 (2016).
8. van Beljouw, S.P.B. et al. The gRAMP CRISPR-Cas effector is an RNA endonuclease complexed with a caspase-like peptidase. *Science* **373**, 1349-1353 (2021).
9. Ozcan, A. et al. Programmable RNA targeting with the single-protein CRISPR effector Cas7-11. *Nature* **597**, 720-725 (2021).
10. Meeske, A.J. & Marraffini, L.A. RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems. *Mol Cell* **71**, 791-801 e3 (2018).
11. Carte, J., Wang, R., Li, H., Terns, R.M. & Terns, M.P. Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. *Genes Dev* **22**, 3489-96 (2008).
12. Kazlauskienė, M., Tamulaitis, G., Kostiuk, G., Venclovas, C. & Siksnys, V. Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition. *Mol Cell* **62**, 295-306 (2016).
13. Sridhara, S. et al. Structural and biochemical characterization of in vivo assembled *Lactococcus lactis* CRISPR-Csm complex. *Commun Biol* **5**, 279 (2022).
14. You, L. et al. Structure Studies of the CRISPR-Csm Complex Reveal Mechanism of Co-transcriptional Interference. *Cell* **176**, 239-253 e16 (2019).
15. Jia, N. et al. Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity. *Mol Cell* **73**, 264-277 e5 (2019).
16. Li, H. Structural Principles of CRISPR RNA Processing. *Structure* **23**, 13-20 (2015).
17. Hochstrasser, M.L. & Doudna, J.A. Cutting it close: CRISPR-associated endoribonuclease structure and function. *Trends Biochem Sci* **40**, 58-66 (2015).
18. Makarova, K.S., Aravind, L., Wolf, Y.I. & Koonin, E.V. Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. *Biol Direct* **6**, 38 (2011).
19. Wang, R. & Li, H. The mysterious RAMP proteins and their roles in small RNA-based immunity. *Protein Sci* **21**, 463-70 (2012).
20. Zheng, S.Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* **14**, 331-332 (2017).

- 1 21. Kimanius, D., Dong, L.Y., Sharov, G., Nakane, T. & Scheres, S.H.W. New tools for
2 automated cryo-EM single-particle analysis in RELION-4.0. *Biochemical Journal* **478**,
3 4169-4185 (2021).
- 4 22. Zhang, K. Gctf: Real-time CTF determination and correction. *J Struct Biol* **193**, 1-12
5 (2016).
- 6 23. Punjani, A., Rubinstein, J.L., Fleet, D.J. & Brubaker, M.A. cryoSPARC: algorithms for
7 rapid unsupervised cryo-EM structure determination. *Nat Methods* **14**, 290-296 (2017).
- 8 24. Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. *Nature* **596**,
9 583-589 (2021).
- 10 25. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta*
11 *Crystallogr D Biol Crystallogr* **60**, 2126-32 (2004).
- 12 26. Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and
13 electrons: recent developments in Phenix. *Acta Crystallographica Section D-Structural*
14 *Biology* **75**, 861-877 (2019).
- 15


a



b




c




a


bioRxiv preprint doi: <https://doi.org/10.1101/2022.06.22.497266>; this version posted June 23, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




b




c




d




a




b




f




c





d




e



a**b****c**

DiCas7-11	-	-	WT	Δint1
crRNA	+	-	+	+
target RNA	-	+	+	+



Supplementary Materials


Molecular Mechanism of Active Cas7-11 in Processing CRISPR RNA and Interfering Target RNA

Hemant Gowswami¹, Jay Rai¹, Anuska Das¹, and Hong Li^{1,2*}


¹Institute of Molecular Biophysics, Florida State University, Florida State University,
Tallahassee, FL, USA

²Department of Chemistry and Biochemistry, Florida State University, Tallahassee, FL 32306,
USA.

Corresponding author: hong.li@fsu.edu




Supplementary Figure 1. Top, schematic of the vector used for over-expression of apo DiCas7-11, the elution profile of DiCas7-11 on size exclusion chromatography, and gel analysis of the purified protein. Bottom, schematic of DiCas7-11 and pre-crRNA incubation for binary complex formation, elution profile of DiCas7-11-crRNA binary complex, and gel analysis of the crRNA in the peak fraction.




Supplementary Figure 2.

Supplementary Figure 2. (a) Work-flow of the cryo-EM image processing and 3D reconstruction of the DiCas7-11 ternary complex. The numbers indicate the number of particles while the percent indicates the percent to the total particles for each class. (b) Fourier Shell Correlations (FSC) of DiCas7-11-crRNA-ternary complex reconstruction, with the FSC cutoff 0.143, marked with a gray line and final resolution. (c) The local resolution of the final density map obtained from ResMap is colored as the color scale bar.




Supplementary Figure 3. Electron potential density maps for selected regions where nucleotide positions are labeled: around the 5' tag region, the crRNA processing site, and the two target cleavage sites.




Supplementary Figure 4

Supplementary Figure 4. Comparison of DiCas7-11 to the homologous multi-subunit Csm complex from *Lactococcus lactis* (LlCsm) (a) and its individual protein domains (b). (a). LlCsm overview in three orientations in cartoon representations. The two left views are oriented exactly the same as those of DiCas7-11 shown in Figure 1. Subunits that superimposed with DiCas7-11 domains and RNA are labeled and colored identically. (b). The four Cas7-like (C7L) domains are superimposed and shown separately in cartoon representations and colored as those in Figure 1. The Cas11-like (C11L) is shown in cartoon representations. Key elements discussed in the text are labels. Boxed structures are the corresponding subunits for C11L and C7L, respectively, from LlCsm (PDB id: 6xn2).



Supplementary Figure 5

Supplementary Figure 5. Schematic RNA-protein interactions observed in the DiCas7-11-crRNA-target RNA ternary complex structure. Protein residues are colored according to the scheme used in Figure 1 that corresponding to respective domains. The black, red and light pink color boxes denote spacer, repeat and target RNA. The green and blue colored triangles indicate target RNA and pre-crRNA processing sites, respectively.



Supplementary Figure 6.

Supplementary Figure 6. Sequence comparison among Cas7-11 proteins overlays with the secondary structure structures of DiCas7. Regions of interests and described in the main text are marked by asterisks. DiCas7-11 is from *Desulfonema ishimotonii*; CjcCas7-11 is from *Candidatus Jettenia caeni*; CsbCas7-11 is from *Candidatus Scalindua broadae*; HsmCas7-11 and SstCas7-11 source organism is unknown.

Supplementary Table 1. Data acquisition and processing parameters. Related to Figures 2-4

Microscope	Titan Krios
Detector	Gatan K3
Voltage	300 kV
Electron Source	Field Emission Gun
Collecting Mode	Counting
Dose Rate (e ⁻ /Å ²)	60.07
Defocus range (μm)	-1.1 to -2.5
Nominal Magnification	105000x
Frames collected per exposure	75
Frame alignment Software	MotionCor2
CTF parameter estimation Software	Gctf
Total number of raw images collected	4177
Number of images used for particle picking	4168
Initial particles picked	1,301,452
2D classification software	Cryo-SPARC
Final reconstruction software	Relion 4.0
Applied symmetry	C1
Number of particles contributed for the final reconstruction	226320
Resolution method	FSC 0.143 cut-off
Map resolution (Å)	2.82
Local resolution determining Software	Relion 4.0
Map Visualization software	Pymol/Chimera/ Chimera X/ Coot
Deposit EMDB code	27138
Refinement parameters	
CC (map_model) (mask)	0.82
RMSD (Bond lengths/Bond angles)	0.002 Å /0.559°
Ramachandran plot (%) (Outlier/Allowed/Favored)	(0.0/5.8/94.2)
Cβ Outliers (%)	0.0
MolProbity Score	2.44
Clash score	36.5
Rotamer outliers (%)	0.0
ADP (B-factor)	Protein 0.00/82.19/25.53
Protein (min/mask/mean) Nucleotides (min/mask/mean)	Nucleotides 0.00/150.16/32.79
dFSC model (0/0.143/0.5)	2.4/2.6/2.8
Deposit PDB code	8D1V

Supplementary Table 2: Ribonucleic acid sequences used in this study. Related to Figures 1-4

Nucleic Acid	Sequence	Source
DiCas_IVT_1_F (WT-pre-crRNA)	5'TAATACGACTCACTATAGGTTGGAAAGCCGGTTTTCTTTGAT GTCACGGAACACGTTCTTTGAACCAAGCTTCAAC 3'	Eurofins
DiCas_IVT_1_R (WT-pre-crRNA)	5'GTTGAAGCTTGGTTCAAAGAACGTGTTCCGTGACATCAAAGA AAACCGGCTTTCCAACCTATAGTGAGTCGTATTA 3'	Eurofins
pre-crDNA1_F (pA1)	5'GAAATTAATACGACTCACTATAGGGGAAAAAAAAAAAAAAAAAA AAATTGATGTCACGGAACACGTTCTTTGAACCAAGCTTCAAC 3'	Eurofins
pre-crDNA1_R (pA1)	5'GTTGAAGCTTGGTTCAAAGAACGTGTTCCGTGACATCAATTT TTTTTTTTTTTTTTTCCCTATAGTGAGTCGTATTAATTTTC 3'	Eurofins
pre-crDNA2_F (pA2)	5'GAAATTAATACGACTCACTATAGGGGAAAAAAAAAAAAAAAAAA TTGATGTCACGGAACACGTTCTTTGAACCAAGCTTCAAC 3'	Eurofins
pre-crDNA2_R (pA2)	5'GTTGAAGCTTGGTTCAAAGAACGTGTTCCGTGACATCAATTT TTTTTTTTTTTTTTTCCCTATAGTGAGTCGTATTAATTTTC 3'	Eurofins
pre-crDNA3_F (pA3)	5'GAAATTAATACGACTCACTATAGGGGAAAAAATTGATGTCAC GGAACACGTTCTTTGAACCAAGCTTCAAC 3'	Eurofins
pre-crDNA3_R (pA3)	5'GTTGAAGCTTGGTTCAAAGAACGTGTTCCGTGACATCAATTT TTTCCCTATAGTGAGTCGTATTAATTTTC 3'	Eurofins
Pre-crDNA4_F (Csb)	5'GAAATTAATACGACTCACTATAGGGTTATGAAACAAGAGAA GGACTTAATGTCACGGTACCGTTCTTTGAACCAAGCTTCAAC 3'	Eurofins
pre-crDNA4_R (Csb)	5'GTTGAAGCTTGGTTCAAAGAACGGTACCGTGACATTAAGTCC TTCTCTTGTTTCATAACCCTATAGTGAGTCGTATTAATTTTC 3'	Eurofins
Target RNA	5'GGAGUUGAAGCUUGGUUCAAAAGAACGUAUCAAGAGCA 3'	IDT
5' Cy3 Target RNA	5'Cy3 GGAGUUGAAGCUUGGUUCAAAAGAACGUAUCAAGAGCA 3'	
Deoxy Target RNA	5'GGAGUUGAAGCUUGGUUCAAAAGAACGUAUCAAGAGCA 3'	IDT
PFS less target RNA (target-RNA2)	5'GGAGUUGAAGCUUGGUUCAAAAGAACGU 3'	
Mature crRNA	5'UGAUGUCACGGAACACGUUCUUUGAACCAAGCUUCAAC 3'	IDT
Deoxy crRNA-16	5'GGUUGGAAAGCCGGUUUUCTUUGAUGUCACGGAACACGUU CUUUGAACCAAGCUUCAAC 3'	IDT
Deoxy crRNA-15	5'GGUUGGAAAGCCGGUUUUCUTUGAUGUCACGGAACACGUU CUUUGAACCAAGCUUCAAC 3'	IDT
Deoxy crRNA-14	5'GGUUGGAAAGCCGGUUUUCUUTGAUGUCACGGAACACGUU CUUUGAACCAAGCUUCAAC 3'	IDT
5' truncated RNA1	UUCAAAAGAACGU	IDT
5' truncated RNA2	UUGGUUCAAAAGAACGU	IDT
3' truncated RNA1	GUUGAAGCUUGGUUCAAAAGACG	IDT

3' truncated RNA2	GUUGAAGCUUGGUUCAA	IDT
Cas7 H43A F	TGCCCCGTTGGGCCCCGCAACAAGAAAGATAAC	Eurofins
Cas7 H43A R	AACGCTTGGCCACGCACA	Eurofins
Cas7 Y360A F	GTGAGGCGCTTGCTTTGAAGAGTAAG	Eurofins
Cas7 Y360A R	CAAGCTTCTCACAAAACTCGC	Eurofins
711 Δ int1 F	CGCGGGCGGTGACCTGAAAGAGAACGAG	Eurofins
711 Δ int1 R	CTGCCACCGCCAGTCTCGGAAAACTTTTGAATG	Eurofins



Full wwPDB EM Validation Report ⓘ

Jun 2, 2022 – 03:20 PM EDT

PDB ID : 8D1V
 EMDB ID : EMD-27138
 Title : Structure of type III-E Cas7-11 from *Desulfonema ishimotonii*
 Deposited on : 2022-05-27
 Resolution : 2.82 Å (reported)

This wwPDB validation report is for manuscript review

This is a Full wwPDB EM Validation Report.

This report is produced by the wwPDB biocuration pipeline after annotation of the structure.

We welcome your comments at validation@mail.wwpdb.org

A user guide is available at

<https://www.wwpdb.org/validation/2017/EMValidationReportHelp>

with specific help available everywhere you see the ⓘ symbol.

The following versions of software and data (see [references ⓘ](#)) were used in the production of this report:


EMDB validation analysis : 0.0.1.dev7
 MolProbity : 4.02b-467
 Percentile statistics : 20191225.v01 (using entries in the PDB archive December 25th 2019)
 Ideal geometry (proteins) : Engh & Huber (2001)
 Ideal geometry (DNA, RNA) : Parkinson et al. (1996)
 Validation Pipeline (wwPDB-VP) : 2.28

1 Overall quality at a glance i

The following experimental techniques were used to determine the structure:
ELECTRON MICROSCOPY

The reported resolution of this entry is 2.82 Å.

Percentile scores (ranging between 0-100) for global validation metrics of the entry are shown in the following graphic. The table shows the number of entries on which the scores are based.



Metric	Whole archive (#Entries)	EM structures (#Entries)
Clashscore	158937	4297
Ramachandran outliers	154571	4023
Sidechain outliers	154315	3826
RNA backbone	4643	859

The table below summarises the geometric issues observed across the polymeric chains and their fit to the map. The red, orange, yellow and green segments of the bar indicate the fraction of residues that contain outliers for ≥ 3 , 2, 1 and 0 types of geometric quality criteria respectively. A grey segment represents the fraction of residues that are not modelled. The numeric value for each fraction is indicated below the corresponding segment, with a dot representing fractions $\leq 5\%$. The upper red bar (where present) indicates the fraction of residues that have poor fit to the EM map (all-atom inclusion $< 40\%$). The numeric value is given above the bar.

Mol	Chain	Length	Quality of chain
1	A	1253	20% 47% 53%
2	N	34	9% 9% 59% 32%
3	J	18	33% 11% 28% 61%

2 Entry composition

There are 3 unique types of molecules in this entry. The entry contains 11148 atoms, of which 9 are hydrogens and 0 are deuteriums.

In the tables below, the AltConf column contains the number of residues with at least one atom in alternate conformation and the Trace column contains the number of residues modelled with at most 2 atoms.

- Molecule 1 is a protein called Di Cas7-11.

Mol	Chain	Residues	Atoms						AltConf	Trace
			Total	C	H	N	O	S		
1	A	1251	10045	6340	9	1797	1852	47	0	0

- Molecule 2 is a RNA chain called CRISPR RNA (34-MER).

Mol	Chain	Residues	Atoms					AltConf	Trace
			Total	C	N	O	P		
2	N	34	716	322	124	237	33	0	0

- Molecule 3 is a RNA chain called SS target RNA (5'-R(P*AP*GP*CP*UP*UP*GP*GP*UP*UP*CP*AP*AP*AP*GP*AP*AP*CP*G)-3').


Mol	Chain	Residues	Atoms					AltConf	Trace
			Total	C	N	O	P		
3	J	18	387	173	72	124	18	0	0

3 Residue-property plots


These plots are drawn for all protein, RNA, DNA and oligosaccharide chains in the entry. The first graphic for a chain summarises the proportions of the various outlier classes displayed in the second graphic. The second graphic shows the sequence view annotated by issues in geometry and atom inclusion in map density. Residues are color-coded according to the number of geometric quality criteria for which they contain at least one outlier: green = 0, yellow = 1, orange = 2 and red = 3 or more. A red diamond above a residue indicates a poor fit to the EM map for this residue (all-atom inclusion < 40%). Stretches of 2 or more consecutive residues without any outlier are shown as a green connector. Residues present in the sample, but not in the model, are shown in grey.

• Molecule 1: Di Cas7-11






• Molecule 2: CRISPR RNA (34-MER)



• Molecule 3: SS target RNA (5'-R(P*AP*GP*CP*UP*UP*GP*GP*UP*UP*CP*AP*AP*AP*GP*AP*AP*CP*G)-3')



4 Experimental information

Property	Value	Source
EM reconstruction method	SINGLE PARTICLE	Depositor
Imposed symmetry	POINT, C1	Depositor
Number of particles used	226320	Depositor
Resolution determination method	FSC 0.143 CUT-OFF	Depositor
CTF correction method	PHASE FLIPPING AND AMPLITUDE CORRECTION	Depositor
Microscope	FEI TITAN KRIOS	Depositor
Voltage (kV)	300	Depositor
Electron dose ($e^-/\text{\AA}^2$)	60	Depositor
Minimum defocus (nm)	1000	Depositor
Maximum defocus (nm)	2200	Depositor
Magnification	Not provided	
Image detector	GATAN K3 BIOQUANTUM (6k x 4k)	Depositor
Maximum map value	0.098	Depositor
Minimum map value	-0.053	Depositor
Average map value	0.000	Depositor
Map value standard deviation	0.003	Depositor
Recommended contour level	0.0146	Depositor
Map size (Å)	249.0, 249.0, 249.0	wwPDB
Map dimensions	300, 300, 300	wwPDB
Map angles (°)	90.0, 90.0, 90.0	wwPDB
Pixel spacing (Å)	0.83, 0.83, 0.83	Depositor

5 Model quality

5.1 Standard geometry

The Z score for a bond length (or angle) is the number of standard deviations the observed value is removed from the expected value. A bond length (or angle) with $|Z| > 5$ is considered an outlier worth inspection. RMSZ is the root-mean-square of all Z scores of the bond lengths (or angles).

Mol	Chain	Bond lengths		Bond angles	
		RMSZ	# Z >5	RMSZ	# Z >5
1	A	0.25	0/10270	0.51	6/13829 (0.0%)
2	N	0.18	0/799	0.73	0/1242
3	J	0.17	0/433	0.71	0/673
All	All	0.25	0/11502	0.54	6/15744 (0.0%)

There are no bond length outliers.

All (6) bond angle outliers are listed below:

Mol	Chain	Res	Type	Atoms	Z	Observed(°)	Ideal(°)
1	A	472	CYS	CA-CB-SG	8.46	129.23	114.00
1	A	463	CYS	CA-CB-SG	7.29	127.13	114.00
1	A	474	CYS	CA-CB-SG	7.25	127.04	114.00
1	A	114	PRO	CA-N-CD	-6.73	102.08	111.50
1	A	114	PRO	N-CD-CG	-5.86	94.41	103.20
1	A	877	GLU	C-N-CA	5.36	135.10	121.70

There are no chirality outliers.

There are no planarity outliers.

5.2 Too-close contacts

In the following table, the Non-H and H(model) columns list the number of non-hydrogen atoms and hydrogen atoms in the chain respectively. The H(added) column lists the number of hydrogen atoms added and optimized by MolProbity. The Clashes column lists the number of clashes within the asymmetric unit, whereas Symm-Clashes lists symmetry-related clashes.

Mol	Chain	Non-H	H(model)	H(added)	Clashes	Symm-Clashes
1	A	10036	9	9939	735	0
2	N	716	0	366	74	0
3	J	387	0	195	31	0
All	All	11139	9	10500	779	0

The all-atom clashscore is defined as the number of clashes found per 1000 atoms (including hydrogen atoms). The all-atom clashscore for this structure is 36.

All (779) close contacts within the same asymmetric unit are listed below, sorted by their clash magnitude.

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:456:GLN:HG2	1:A:462:PRO:HB3	1.21	1.18
1:A:720:ALA:HB2	2:N:16:A:H4'	1.22	1.14
1:A:295:SER:HB3	1:A:298:LEU:HB2	1.23	1.12
1:A:827:LYS:HD3	1:A:828:ARG:H	1.14	1.10
1:A:877:GLU:HG2	1:A:878:GLU:HB3	1.25	1.08
1:A:28:LYS:HE3	1:A:388:ARG:HD2	1.37	1.06
1:A:75:LEU:HD21	1:A:401:LEU:HD22	1.39	1.02
1:A:44:ARG:HD2	1:A:50:THR:HA	1.42	1.01
1:A:708:CYS:HB2	1:A:711:CYS:H	1.27	0.99
1:A:474:CYS:H	1:A:477:CYS:HB2	1.27	0.98
1:A:614:LEU:HD12	1:A:615:PRO:HD2	1.47	0.96
1:A:28:LYS:CE	1:A:388:ARG:HD2	1.97	0.94
1:A:876:ARG:HB2	1:A:1339:LYS:HD2	1.47	0.94
1:A:688:ALA:HB2	1:A:710:LEU:HD11	1.49	0.93
1:A:689:ARG:HA	1:A:698:LEU:HD21	1.50	0.90
1:A:877:GLU:HG2	1:A:878:GLU:CB	2.01	0.89
1:A:628:ILE:HD12	1:A:825:ASP:HB2	1.54	0.89
1:A:444:ARG:HB2	1:A:485:VAL:HG23	1.53	0.87
1:A:301:GLY:HA3	1:A:650:LYS:HE3	1.57	0.87
2:N:3:G:OP2	2:N:3:G:N2	2.09	0.86
1:A:21:GLN:NE2	1:A:32:GLU:OE2	2.09	0.85
1:A:1458:ILE:HD12	1:A:1475:LEU:HD11	1.59	0.84
1:A:1486:GLY:O	1:A:1489:LYS:NZ	2.10	0.84
1:A:7:ILE:HG21	1:A:204:ILE:HD12	1.59	0.84
1:A:880:PRO:HB3	1:A:1346:ARG:HG2	1.58	0.83
1:A:154:SER:HG	2:N:1:U:H3	0.88	0.83
1:A:403:GLU:O	1:A:580:LEU:N	2.11	0.83
1:A:278:LYS:HG3	1:A:317:ILE:HG21	1.59	0.83
3:J:18:A:H2'	3:J:19:G:H5''	1.60	0.82
3:J:21:A:H4'	3:J:22:C:OP2	1.79	0.82
1:A:827:LYS:CD	1:A:828:ARG:H	1.92	0.81
2:N:32:G:H2'	2:N:33:C:C6	2.14	0.81
1:A:399:SER:O	1:A:583:SER:OG	1.99	0.81
1:A:1423:THR:HG22	1:A:1428:ASN:HB2	1.62	0.81
1:A:193:ASP:OD2	1:A:195:THR:OG1	1.99	0.81
1:A:278:LYS:HE3	1:A:317:ILE:HG23	1.63	0.80
1:A:1393:ARG:HA	2:N:28:C:O2'	1.81	0.80

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:295:SER:HB3	1:A:298:LEU:CB	2.11	0.80
1:A:977:TRP:HZ3	1:A:1297:ASP:HB2	1.45	0.80
1:A:304:LYS:NZ	1:A:310:ASP:OD2	2.15	0.79
1:A:754:LYS:N	3:J:14:U:O2'	2.15	0.79
1:A:708:CYS:CB	1:A:711:CYS:H	1.95	0.79
1:A:1:MET:SD	1:A:145:ARG:NH1	2.56	0.79
1:A:290:ARG:O	1:A:293:ARG:HG3	1.83	0.78
1:A:1:MET:HG3	1:A:2:THR:HG23	1.65	0.78
1:A:827:LYS:HD3	1:A:828:ARG:N	1.97	0.78
1:A:875:GLU:OE2	1:A:877:GLU:HB3	1.82	0.78
1:A:844:VAL:HG23	1:A:1519:ILE:HD12	1.64	0.78
1:A:876:ARG:NH2	1:A:1308:ASP:O	2.17	0.78
1:A:720:ALA:CB	2:N:16:A:H4'	2.11	0.77
1:A:1395:ARG:HH12	2:N:31:A:H1'	1.50	0.77
2:N:14:A:O2'	2:N:15:C:OP2	2.02	0.77
1:A:123:CYS:HB2	1:A:124:PRO:HD2	1.67	0.77
1:A:85:CYS:HA	1:A:123:CYS:SG	2.24	0.77
1:A:708:CYS:HB2	1:A:711:CYS:N	1.99	0.77
1:A:1394:PRO:HD3	2:N:28:C:O2'	1.84	0.77
1:A:67:ARG:HG2	1:A:104:ARG:HH21	1.48	0.76
1:A:295:SER:OG	1:A:298:LEU:HD12	1.84	0.76
1:A:86:CYS:N	1:A:123:CYS:SG	2.58	0.76
1:A:614:LEU:CD1	1:A:615:PRO:HD2	2.15	0.76
1:A:1565:ARG:HE	1:A:1567:LYS:HE3	1.51	0.76
1:A:470:ARG:HD3	1:A:471:PRO:HD2	1.68	0.76
1:A:474:CYS:N	1:A:477:CYS:HB2	2.01	0.76
1:A:123:CYS:SG	1:A:126:CYS:HB2	2.26	0.75
1:A:1424:ILE:CD1	1:A:1491:MET:HB3	2.16	0.75
1:A:778:ILE:HD11	1:A:782:VAL:HG11	1.69	0.75
2:N:3:G:H1'	2:N:4:A:C8	2.21	0.75
1:A:456:GLN:CG	1:A:462:PRO:HB3	2.10	0.75
1:A:281:TYR:HB3	1:A:314:LEU:CD1	2.18	0.74
1:A:1299:ARG:HG2	1:A:1303:LYS:HG3	1.69	0.74
3:J:6:A:H2'	3:J:7:G:C8	2.23	0.73
1:A:176:VAL:HA	1:A:183:ALA:HA	1.69	0.73
1:A:916:PHE:HB2	1:A:933:SER:HB3	1.69	0.73
1:A:698:LEU:HD13	1:A:885:LYS:HB3	1.70	0.73
1:A:541:LEU:HD23	1:A:545:LEU:HG	1.70	0.73
1:A:680:ARG:NH2	1:A:714:PHE:O	2.22	0.73
1:A:576:LYS:HG2	1:A:612:SER:HA	1.70	0.73
1:A:1310:ARG:HG3	1:A:1311:PRO:HD2	1.69	0.73

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:514:GLY:CA	3:J:22:C:H4'	2.19	0.73
1:A:873:LYS:O	1:A:963:ASN:ND2	2.22	0.73
1:A:92:THR:HG22	2:N:6:G:N7	2.04	0.72
1:A:876:ARG:HB2	1:A:1339:LYS:CD	2.17	0.72
1:A:1390:LEU:HD12	1:A:1391:LEU:H	1.54	0.72
1:A:1401:PRO:HB2	1:A:1586:LYS:HD3	1.71	0.72
1:A:404:THR:HG21	1:A:541:LEU:HD12	1.71	0.72
1:A:1437:GLU:N	1:A:1437:GLU:OE1	2.22	0.71
1:A:822:ILE:HG12	1:A:833:MET:HE1	1.71	0.71
2:N:2:U:O2'	2:N:3:G:O5'	2.07	0.71
1:A:321:LYS:HD2	1:A:321:LYS:O	1.90	0.71
1:A:917:ARG:HH22	1:A:930:TYR:HB2	1.54	0.71
1:A:1445:VAL:HG11	1:A:1487:MET:HE3	1.72	0.71
1:A:403:GLU:HB3	1:A:580:LEU:HB2	1.71	0.71
1:A:1328:TYR:HB3	1:A:1331:LYS:HB2	1.71	0.71
1:A:182:LYS:HD2	1:A:718:TYR:HA	1.72	0.71
1:A:391:LYS:NZ	1:A:392:SER:O	2.24	0.71
1:A:549:LEU:HB3	1:A:614:LEU:HD21	1.73	0.70
1:A:404:THR:HG21	1:A:541:LEU:CD1	2.22	0.70
1:A:1582:GLY:O	1:A:1585:LYS:NZ	2.17	0.70
1:A:728:LEU:HB3	1:A:772:LEU:HG	1.74	0.70
1:A:695:GLY:N	1:A:696:VAL:HA	2.06	0.70
1:A:796:LEU:HD22	1:A:820:LEU:HD21	1.74	0.70
1:A:712:GLN:OE1	1:A:788:TYR:OH	2.09	0.70
1:A:513:GLU:OE2	1:A:1333:LEU:HD21	1.92	0.69
1:A:847:LYS:NZ	1:A:1497:GLU:OE2	2.24	0.69
1:A:1565:ARG:NE	1:A:1567:LYS:HE3	2.05	0.69
1:A:330:ARG:O	1:A:334:THR:HG23	1.92	0.69
1:A:565:THR:HG21	1:A:677:GLU:HG3	1.74	0.69
1:A:1347:LEU:CD1	1:A:1463:LEU:HD21	2.21	0.69
1:A:1483:HIS:HB2	1:A:1496:VAL:HG23	1.75	0.69
1:A:803:LEU:HD21	1:A:886:PHE:CZ	2.28	0.69
1:A:783:LEU:HD11	1:A:825:ASP:OD1	1.91	0.69
1:A:75:LEU:HD11	1:A:401:LEU:HB3	1.74	0.69
1:A:146:PHE:HB2	1:A:149:HIS:HB2	1.75	0.69
1:A:894:LYS:HD2	1:A:1457:GLU:OE2	1.93	0.69
2:N:26:A:O2'	2:N:27:A:OP2	2.09	0.69
3:J:18:A:C2'	3:J:19:G:H5''	2.22	0.69
1:A:336:SER:O	1:A:342:LEU:HD12	1.93	0.68
1:A:486:MET:HB3	1:A:531:GLN:HB3	1.73	0.68
1:A:87:PRO:HG2	1:A:114:PRO:HG3	1.75	0.68

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:728:LEU:CD2	1:A:774:GLY:HA3	2.22	0.68
1:A:453:ARG:O	1:A:457:THR:HG23	1.93	0.68
1:A:698:LEU:O	1:A:700:GLU:HG2	1.94	0.68
1:A:266:ALA:O	1:A:270:ILE:HG23	1.93	0.68
1:A:265:THR:O	1:A:269:ILE:HG12	1.93	0.68
1:A:486:MET:CB	1:A:531:GLN:HB3	2.24	0.68
1:A:403:GLU:N	1:A:580:LEU:O	2.27	0.68
1:A:632:ILE:HG12	1:A:820:LEU:HD13	1.75	0.67
1:A:443:PRO:O	1:A:447:VAL:HG23	1.94	0.67
1:A:532:LEU:HD23	1:A:549:LEU:HD11	1.76	0.67
1:A:977:TRP:CZ3	1:A:1297:ASP:HB2	2.29	0.67
1:A:47:LYS:HG3	1:A:48:ASP:H	1.60	0.67
1:A:470:ARG:HD3	1:A:471:PRO:CD	2.24	0.67
1:A:524:GLU:OE2	1:A:660:LYS:NZ	2.24	0.67
1:A:7:ILE:HD13	1:A:204:ILE:HD11	1.77	0.67
1:A:177:ASP:HB2	1:A:184:HIS:CD2	2.29	0.67
1:A:910:THR:HG21	2:N:26:A:C8	2.30	0.66
1:A:745:ASP:OD1	1:A:969:PHE:HA	1.95	0.66
1:A:492:TYR:CZ	1:A:494:ALA:HB3	2.30	0.66
1:A:1302:GLY:O	1:A:1310:ARG:NH2	2.28	0.66
1:A:955:SER:HB3	1:A:1348:PHE:CE2	2.31	0.66
1:A:556:GLN:NE2	1:A:625:TRP:HB2	2.10	0.66
1:A:549:LEU:HD22	1:A:572:MET:CE	2.26	0.66
1:A:95:LYS:NZ	1:A:97:ARG:O	2.29	0.65
1:A:447:VAL:HG13	1:A:559:MET:HE1	1.77	0.65
2:N:14:A:H1'	2:N:15:C:C5	2.31	0.65
2:N:18:G:H3'	2:N:19:U:H5''	1.79	0.65
1:A:916:PHE:HB2	1:A:933:SER:CB	2.26	0.65
1:A:34:VAL:HG22	1:A:99:LEU:HD11	1.79	0.65
1:A:703:HIS:ND1	1:A:711:CYS:SG	2.70	0.65
1:A:863:TYR:OH	2:N:30:A:OP2	2.14	0.65
1:A:1341:LEU:HD22	1:A:1345:CYS:HB3	1.77	0.65
1:A:132:SER:HB2	1:A:135:ASP:OD2	1.96	0.65
1:A:674:TYR:HB3	1:A:728:LEU:HB2	1.77	0.65
1:A:516:LEU:HD21	2:N:20:U:O4	1.96	0.65
1:A:555:GLY:O	1:A:569:ARG:NH1	2.30	0.65
1:A:692:MET:O	1:A:694:ASP:HA	1.96	0.65
1:A:470:ARG:CD	1:A:471:PRO:HD2	2.28	0.64
1:A:778:ILE:HD11	1:A:782:VAL:CG1	2.27	0.64
1:A:822:ILE:HG12	1:A:833:MET:CE	2.26	0.64
2:N:14:A:H1'	2:N:15:C:C6	2.32	0.64

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:551:TRP:O	1:A:554:GLU:HG2	1.97	0.64
1:A:698:LEU:O	1:A:698:LEU:HD23	1.97	0.64
1:A:305:ASP:OD2	1:A:310:ASP:N	2.30	0.64
1:A:430:LEU:HB2	1:A:519:MET:CB	2.27	0.64
1:A:578:GLU:HB2	1:A:610:LEU:CD2	2.28	0.64
1:A:978:ARG:NH2	2:N:31:A:H5'	2.13	0.64
1:A:17:MET:CE	1:A:167:ILE:HD11	2.28	0.64
1:A:264:LYS:O	1:A:267:GLU:HG3	1.98	0.64
1:A:320:LYS:O	1:A:321:LYS:HG3	1.98	0.64
1:A:578:GLU:HB2	1:A:610:LEU:HD23	1.80	0.64
1:A:917:ARG:HG3	1:A:918:PRO:HD2	1.80	0.64
1:A:964:SER:HB3	1:A:1342:CYS:SG	2.38	0.64
1:A:1332:ARG:O	1:A:1332:ARG:HG2	1.96	0.64
1:A:1585:LYS:HG3	1:A:1586:LYS:H	1.63	0.64
1:A:67:ARG:HG2	1:A:104:ARG:NH2	2.12	0.64
1:A:307:ASP:HB2	1:A:309:LYS:HD3	1.79	0.63
2:N:18:G:H3'	2:N:19:U:C5'	2.28	0.63
1:A:708:CYS:O	1:A:712:GLN:HG2	1.98	0.63
1:A:1424:ILE:HD11	1:A:1491:MET:HB3	1.79	0.63
1:A:747:PHE:CE1	1:A:1410:PRO:HD2	2.34	0.63
1:A:269:ILE:HD11	1:A:332:ILE:HG21	1.80	0.63
1:A:277:LYS:O	1:A:279:THR:HG23	1.98	0.63
1:A:405:VAL:O	1:A:577:TYR:HA	1.98	0.63
1:A:31:LYS:HZ2	1:A:385:LYS:HD2	1.63	0.63
1:A:303:PRO:HB3	1:A:652:GLY:HA2	1.79	0.63
1:A:433:LEU:CD2	1:A:443:PRO:HG3	2.28	0.63
1:A:1580:LYS:O	1:A:1585:LYS:HA	1.99	0.63
1:A:1583:GLU:HG2	1:A:1584:PHE:CD1	2.34	0.63
2:N:22:U:H2'	2:N:23:U:C6	2.34	0.63
1:A:96:ASP:O	1:A:388:ARG:NH2	2.31	0.63
1:A:444:ARG:NH2	2:N:10:C:OP2	2.21	0.63
1:A:706:CYS:SG	1:A:708:CYS:N	2.71	0.63
1:A:28:LYS:HE3	1:A:388:ARG:HH11	1.64	0.63
1:A:281:TYR:HB3	1:A:314:LEU:HD12	1.81	0.63
1:A:474:CYS:O	1:A:478:ARG:N	2.32	0.63
1:A:713:ILE:HG21	1:A:792:LEU:HD21	1.79	0.63
1:A:881:CYS:HB3	1:A:890:ARG:NH2	2.14	0.63
2:N:2:U:OP2	2:N:2:U:H3'	1.99	0.63
1:A:917:ARG:NH2	1:A:930:TYR:HB2	2.14	0.62
1:A:7:ILE:HD13	1:A:204:ILE:CD1	2.29	0.62
1:A:472:CYS:O	1:A:477:CYS:HB3	1.99	0.62

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:1503:VAL:HG11	1:A:1522:TRP:CZ3	2.34	0.62
1:A:174:ASN:HA	1:A:186:PHE:HA	1.81	0.62
1:A:417:PHE:O	1:A:560:SER:HB2	1.98	0.62
1:A:406:VAL:HA	1:A:576:LYS:O	1.99	0.62
1:A:547:THR:HG22	1:A:617:PRO:CB	2.28	0.62
1:A:628:ILE:CD1	1:A:825:ASP:HB2	2.30	0.62
1:A:51:LYS:HA	1:A:161:PHE:O	1.99	0.62
1:A:319:LYS:HB3	1:A:328:THR:CG2	2.30	0.62
1:A:514:GLY:HA3	3:J:22:C:H4'	1.81	0.62
1:A:864:PRO:HA	1:A:1559:VAL:CG1	2.30	0.61
1:A:697:PRO:HB2	1:A:701:LEU:HD11	1.80	0.61
1:A:28:LYS:HE3	1:A:388:ARG:CD	2.24	0.61
1:A:1414:PHE:HB2	1:A:1547:LEU:HD13	1.81	0.61
1:A:17:MET:O	1:A:190:TYR:HB2	2.01	0.61
1:A:532:LEU:CD2	1:A:549:LEU:HD11	2.30	0.61
1:A:1535:ARG:O	1:A:1536:ASP:OD1	2.19	0.61
1:A:483:ILE:HD11	1:A:545:LEU:HD21	1.82	0.61
1:A:703:HIS:ND1	1:A:708:CYS:SG	2.69	0.61
1:A:895:ILE:HG13	1:A:1460:PHE:HE1	1.65	0.61
1:A:411:VAL:CG2	1:A:573:GLU:HG3	2.30	0.61
1:A:1503:VAL:HG11	1:A:1522:TRP:CH2	2.35	0.61
1:A:582:LEU:O	1:A:588:ARG:HB2	1.99	0.61
1:A:895:ILE:HD11	1:A:1468:LEU:HD11	1.83	0.61
1:A:1508:ASP:OD1	1:A:1510:LYS:HG2	2.01	0.61
1:A:898:LYS:HE3	1:A:1501:GLU:OE2	2.00	0.61
1:A:978:ARG:HH21	2:N:31:A:H5"	1.66	0.61
1:A:167:ILE:HG22	1:A:197:PHE:CZ	2.35	0.60
1:A:698:LEU:HD13	1:A:885:LYS:CB	2.31	0.60
1:A:7:ILE:HG21	1:A:204:ILE:CD1	2.29	0.60
1:A:95:LYS:HG3	1:A:97:ARG:H	1.66	0.60
1:A:549:LEU:CB	1:A:614:LEU:HD21	2.30	0.60
1:A:693:GLU:HG2	1:A:694:ASP:HB3	1.82	0.60
1:A:108:ARG:NH2	1:A:394:SER:HB2	2.17	0.60
1:A:1460:PHE:CD2	1:A:1463:LEU:HD12	2.37	0.60
1:A:1529:LYS:HE3	1:A:1533:TRP:NE1	2.17	0.60
1:A:850:THR:HA	1:A:1478:GLU:OE1	2.02	0.60
1:A:132:SER:OG	1:A:135:ASP:HB2	2.02	0.60
1:A:768:ARG:HD2	1:A:940:HIS:CG	2.36	0.60
1:A:44:ARG:CD	1:A:50:THR:HA	2.26	0.60
1:A:803:LEU:HD21	1:A:886:PHE:CE2	2.36	0.60
1:A:1387:MET:SD	1:A:1438:GLN:HG2	2.42	0.60

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:1404:ASP:HB3	1:A:1407:PHE:CE2	2.37	0.60
1:A:6:LYS:O	1:A:237:PHE:HA	2.02	0.59
1:A:41:ARG:NH1	1:A:57:THR:HG21	2.17	0.59
1:A:1534:PHE:HB2	1:A:1538:LEU:CD2	2.32	0.59
1:A:429:ASP:HB3	3:J:22:C:H41	1.66	0.59
1:A:1466:TRP:HB2	1:A:1526:GLY:HA2	1.83	0.59
1:A:127:GLU:HG2	1:A:147:ARG:NH1	2.18	0.59
1:A:328:THR:N	1:A:331:GLN:OE1	2.25	0.59
1:A:502:THR:HA	1:A:515:ALA:O	2.02	0.59
1:A:554:GLU:OE2	1:A:623:PRO:HG3	2.01	0.59
1:A:79:LYS:HE2	1:A:82:GLU:HA	1.84	0.59
1:A:977:TRP:CD1	1:A:1397:THR:HG23	2.38	0.59
1:A:483:ILE:HD11	1:A:545:LEU:CD2	2.33	0.59
1:A:955:SER:O	1:A:959:GLU:HG3	2.03	0.59
3:J:18:A:C3'	3:J:19:G:H5''	2.32	0.59
1:A:31:LYS:NZ	1:A:385:LYS:HD2	2.17	0.59
1:A:305:ASP:OD1	1:A:307:ASP:N	2.35	0.59
1:A:966:PHE:O	1:A:1311:PRO:HG3	2.02	0.59
1:A:85:CYS:SG	1:A:124:PRO:HG2	2.43	0.59
1:A:302:LEU:HB3	1:A:303:PRO:HD2	1.85	0.59
1:A:692:MET:HB3	1:A:696:VAL:HG12	1.85	0.59
1:A:328:THR:OG1	1:A:331:GLN:HG3	2.03	0.59
1:A:903:THR:HB	1:A:904:PRO:HD2	1.85	0.58
1:A:1432:THR:OG1	1:A:1434:LYS:HG2	2.02	0.58
1:A:1549:TRP:NE1	1:A:1552:GLU:OE1	2.35	0.58
1:A:65:VAL:O	1:A:221:SER:OG	2.17	0.58
1:A:128:LEU:HD22	1:A:217:LEU:HD23	1.84	0.58
1:A:174:ASN:O	2:N:13:A:H5''	2.03	0.58
1:A:318:GLY:O	1:A:326:SER:HB2	2.03	0.58
1:A:898:LYS:HB2	1:A:1501:GLU:OE2	2.02	0.58
1:A:1299:ARG:HG2	1:A:1303:LYS:CG	2.33	0.58
1:A:9:ILE:HG22	1:A:235:ILE:HG12	1.86	0.58
1:A:9:ILE:HD11	1:A:56:ILE:HD12	1.83	0.58
1:A:301:GLY:CA	1:A:650:LYS:HE3	2.32	0.58
1:A:737:VAL:O	1:A:760:SER:HA	2.04	0.58
1:A:943:ILE:HD11	1:A:1370:TRP:CZ2	2.37	0.58
1:A:844:VAL:HG23	1:A:1519:ILE:CD1	2.32	0.58
3:J:16:A:O2'	3:J:17:A:H5'	2.03	0.58
1:A:41:ARG:HD2	1:A:57:THR:CG2	2.32	0.58
1:A:30:ASN:O	1:A:34:VAL:HG23	2.03	0.58
1:A:478:ARG:HG2	1:A:481:ARG:HH22	1.69	0.58

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:1539:ASP:OD1	1:A:1540:PHE:N	2.37	0.58
1:A:75:LEU:CD2	1:A:401:LEU:HD22	2.24	0.57
1:A:108:ARG:HH21	1:A:394:SER:HB2	1.69	0.57
1:A:1565:ARG:NH2	3:J:8:C:O2'	2.24	0.57
1:A:626:HIS:HB2	1:A:780:ARG:NH2	2.19	0.57
1:A:845:PRO:HG2	1:A:1520:PRO:HD3	1.86	0.57
1:A:1364:LEU:HD13	1:A:1454:PHE:CZ	2.39	0.57
1:A:868:VAL:CG2	1:A:1547:LEU:HD12	2.34	0.57
1:A:1458:ILE:HD12	1:A:1475:LEU:CD1	2.33	0.57
1:A:633:GLU:HG2	1:A:818:LYS:HB3	1.85	0.57
1:A:695:GLY:HA2	1:A:696:VAL:HG22	1.87	0.57
1:A:1583:GLU:HB2	1:A:1592:LYS:HE3	1.85	0.57
1:A:292:LEU:HA	1:A:295:SER:OG	2.05	0.57
1:A:492:TYR:OH	1:A:494:ALA:HB3	2.04	0.57
1:A:177:ASP:HB2	1:A:184:HIS:NE2	2.19	0.57
1:A:951:ARG:NE	2:N:24:U:OP1	2.27	0.57
1:A:822:ILE:O	1:A:824:GLY:N	2.36	0.57
1:A:443:PRO:HA	1:A:487:ASP:OD1	2.05	0.57
1:A:577:TYR:O	1:A:578:GLU:HG2	2.05	0.56
1:A:691:HIS:O	1:A:698:LEU:HG	2.05	0.56
1:A:12:LEU:HD13	1:A:598:ARG:O	2.05	0.56
1:A:1395:ARG:NH1	2:N:31:A:H1'	2.17	0.56
2:N:9:A:H4'	2:N:10:C:H5''	1.86	0.56
1:A:86:CYS:HB2	1:A:114:PRO:HA	1.88	0.56
1:A:278:LYS:HG3	1:A:317:ILE:CG2	2.32	0.56
1:A:319:LYS:HB3	1:A:328:THR:HG22	1.87	0.56
1:A:565:THR:CG2	1:A:677:GLU:HG3	2.35	0.56
1:A:628:ILE:HD12	1:A:825:ASP:CB	2.32	0.56
1:A:696:VAL:N	1:A:697:PRO:HD3	2.20	0.56
1:A:80:ILE:HD13	1:A:217:LEU:HB2	1.85	0.56
1:A:338:ASP:OD1	1:A:343:LYS:HD3	2.05	0.56
1:A:900:ILE:HG22	1:A:1497:GLU:HB3	1.88	0.56
1:A:502:THR:CG2	1:A:516:LEU:HD13	2.35	0.56
1:A:743:ALA:HB2	2:N:24:U:H1'	1.88	0.56
1:A:1487:MET:HB3	2:N:27:A:O5'	2.06	0.56
1:A:1401:PRO:HB2	1:A:1586:LYS:CD	2.35	0.56
1:A:9:ILE:HG22	1:A:235:ILE:HG23	1.87	0.55
3:J:6:A:O2'	3:J:7:G:OP1	2.21	0.55
1:A:585:GLU:OE1	1:A:588:ARG:NH2	2.39	0.55
1:A:662:LYS:O	1:A:668:ALA:HA	2.05	0.55
1:A:8:SER:HB2	1:A:199:ARG:HE	1.71	0.55

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:895:ILE:HD11	1:A:1468:LEU:CD1	2.36	0.55
1:A:89:LYS:HD3	2:N:5:U:C2	2.41	0.55
1:A:336:SER:HA	1:A:339:THR:CG2	2.37	0.55
1:A:578:GLU:HG2	1:A:610:LEU:HA	1.88	0.55
3:J:6:A:H4'	3:J:7:G:OP1	2.07	0.55
1:A:117:ASP:HA	1:A:122:TYR:OH	2.07	0.55
1:A:549:LEU:HD22	1:A:572:MET:HE1	1.88	0.55
1:A:687:VAL:O	1:A:691:HIS:ND1	2.33	0.55
1:A:826:ASP:O	1:A:828:ARG:NE	2.39	0.55
1:A:944:MET:CE	1:A:1361:PHE:HB3	2.37	0.55
1:A:437:ASP:O	1:A:438:ASN:HB2	2.06	0.55
1:A:632:ILE:HG12	1:A:820:LEU:CD1	2.36	0.55
2:N:21:C:H2'	2:N:22:U:H6	1.71	0.55
1:A:482:GLY:O	1:A:534:TYR:HA	2.07	0.55
1:A:732:SER:O	1:A:734:PRO:HD3	2.06	0.55
2:N:2:U:H2'	2:N:3:G:N3	2.22	0.55
1:A:474:CYS:O	1:A:477:CYS:N	2.41	0.55
1:A:1356:ARG:NH1	1:A:1462:ASN:O	2.38	0.55
1:A:125:PHE:HA	1:A:217:LEU:CD2	2.36	0.54
1:A:877:GLU:HG2	1:A:878:GLU:CA	2.36	0.54
1:A:105:SER:HB2	1:A:393:ARG:O	2.06	0.54
1:A:895:ILE:HG13	1:A:1460:PHE:CE1	2.41	0.54
1:A:1468:LEU:O	1:A:1472:ILE:HG13	2.07	0.54
1:A:260:ASN:HB2	1:A:264:LYS:HZ3	1.72	0.54
1:A:478:ARG:HG2	1:A:481:ARG:NH2	2.22	0.54
1:A:709:LEU:HD21	1:A:791:ALA:CB	2.38	0.54
1:A:785:ASP:OD1	1:A:787:GLU:HG2	2.06	0.54
1:A:71:ASN:O	1:A:75:LEU:HD23	2.07	0.54
1:A:232:LEU:HD12	1:A:486:MET:SD	2.47	0.54
1:A:1347:LEU:HD13	1:A:1463:LEU:HD21	1.88	0.54
1:A:9:ILE:HD11	1:A:56:ILE:CD1	2.38	0.54
1:A:728:LEU:HD22	1:A:774:GLY:HA3	1.88	0.54
1:A:1486:GLY:O	2:N:27:A:H5''	2.07	0.54
1:A:25:ARG:O	1:A:30:ASN:ND2	2.25	0.54
1:A:98:LEU:HG	1:A:98:LEU:O	2.08	0.54
1:A:877:GLU:O	1:A:1346:ARG:NH2	2.41	0.54
1:A:320:LYS:O	1:A:320:LYS:HG3	2.07	0.54
1:A:1431:THR:OG1	1:A:1560:CYS:HB2	2.08	0.54
1:A:336:SER:HA	1:A:339:THR:HG23	1.88	0.54
1:A:411:VAL:HG21	1:A:573:GLU:HG3	1.89	0.54
1:A:1395:ARG:NH2	3:J:11:G:H21	2.06	0.54

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:293:ARG:CD	1:A:353:GLU:HG2	2.37	0.54
1:A:556:GLN:NE2	1:A:623:PRO:HB2	2.22	0.54
1:A:499:ARG:O	1:A:518:ASN:HA	2.08	0.54
1:A:803:LEU:HD11	1:A:886:PHE:HZ	1.71	0.54
2:N:3:G:H1'	2:N:4:A:N7	2.23	0.54
1:A:10:GLU:HA	1:A:198:PRO:O	2.08	0.53
2:N:27:A:H2'	2:N:28:C:O4'	2.09	0.53
1:A:978:ARG:NH2	2:N:31:A:OP2	2.41	0.53
1:A:70:GLU:OE2	1:A:102:ARG:NH2	2.40	0.53
1:A:389:LEU:HD12	1:A:390:GLU:O	2.09	0.53
1:A:393:ARG:HG2	1:A:470:ARG:HH12	1.74	0.53
1:A:534:TYR:CE2	1:A:542:PRO:HD3	2.43	0.53
1:A:880:PRO:CB	1:A:1346:ARG:HG2	2.35	0.53
1:A:1334:LEU:HD21	1:A:1353:TYR:HB2	1.90	0.53
1:A:1466:TRP:CZ3	1:A:1467:GLU:HG2	2.43	0.53
1:A:65:VAL:HG13	1:A:221:SER:HB3	1.90	0.53
1:A:415:PRO:HB3	1:A:521:VAL:CG1	2.38	0.53
1:A:450:ILE:HG13	1:A:559:MET:HA	1.89	0.53
1:A:713:ILE:HD11	1:A:788:TYR:CD1	2.43	0.53
1:A:293:ARG:HD3	1:A:353:GLU:HG2	1.91	0.53
1:A:944:MET:HE2	1:A:1361:PHE:HB3	1.90	0.53
1:A:80:ILE:CD1	1:A:217:LEU:HB2	2.39	0.53
1:A:485:VAL:H	2:N:10:C:H5	1.56	0.53
1:A:593:LYS:HD3	1:A:593:LYS:N	2.23	0.53
1:A:822:ILE:O	1:A:822:ILE:HG13	2.09	0.53
1:A:902:LYS:HE2	1:A:1497:GLU:HB2	1.91	0.53
1:A:349:ARG:O	1:A:353:GLU:HG3	2.09	0.53
1:A:400:VAL:HG23	1:A:537:SER:HA	1.89	0.53
1:A:458:TYR:HE2	1:A:547:THR:HG21	1.74	0.53
1:A:977:TRP:NE1	1:A:1397:THR:HG23	2.24	0.53
1:A:1407:PHE:O	1:A:1408:LYS:HD3	2.07	0.53
1:A:409:GLU:HB3	1:A:527:VAL:CG1	2.39	0.53
1:A:497:GLU:HG2	1:A:661:TYR:HD2	1.74	0.53
1:A:1423:THR:CG2	1:A:1428:ASN:HB2	2.35	0.53
2:N:8:C:H3'	2:N:11:G:N2	2.24	0.53
3:J:21:A:C4'	3:J:22:C:OP2	2.54	0.53
1:A:87:PRO:HG3	1:A:112:LYS:O	2.10	0.52
1:A:796:LEU:CD2	1:A:820:LEU:HD21	2.38	0.52
1:A:290:ARG:HG3	1:A:427:GLN:OE1	2.09	0.52
1:A:549:LEU:HD22	1:A:572:MET:HE3	1.90	0.52
1:A:1304:ARG:O	1:A:1408:LYS:HD2	2.10	0.52

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:152:ASN:HD21	2:N:2:U:H5'	1.75	0.52
3:J:8:C:HO2'	3:J:9:U:H6	1.55	0.52
3:J:22:C:O2'	3:J:23:G:P	2.67	0.52
1:A:185:ASP:OD2	1:A:382:PHE:N	2.43	0.52
1:A:459:PHE:CZ	1:A:475:LYS:HB3	2.45	0.52
1:A:547:THR:HG22	1:A:617:PRO:HB2	1.91	0.52
1:A:709:LEU:HD21	1:A:791:ALA:HB1	1.92	0.52
3:J:9:U:O2	3:J:10:U:H1'	2.10	0.52
1:A:401:LEU:O	1:A:582:LEU:HB2	2.09	0.52
1:A:75:LEU:HD21	1:A:401:LEU:CD2	2.27	0.52
1:A:207:ASP:OD1	1:A:208:ASN:N	2.43	0.52
1:A:542:PRO:HG2	1:A:545:LEU:HB2	1.92	0.52
1:A:698:LEU:HD22	1:A:884:GLN:O	2.10	0.52
1:A:1445:VAL:HG11	1:A:1487:MET:CE	2.39	0.52
1:A:550:LYS:HD3	1:A:620:TYR:CE1	2.45	0.52
1:A:634:MET:CE	1:A:638:PHE:HB2	2.40	0.52
1:A:9:ILE:O	1:A:9:ILE:HG13	2.09	0.52
1:A:827:LYS:HE2	1:A:831:ARG:HD2	1.91	0.51
1:A:957:VAL:O	1:A:961:VAL:HG23	2.10	0.51
1:A:550:LYS:HD3	1:A:620:TYR:CD1	2.46	0.51
1:A:719:GLU:HA	1:A:719:GLU:OE1	2.10	0.51
1:A:1564:LEU:HD22	2:N:31:A:H62	1.75	0.51
1:A:556:GLN:HE21	1:A:625:TRP:HB2	1.75	0.51
1:A:1390:LEU:HD12	1:A:1391:LEU:N	2.25	0.51
1:A:927:LYS:O	1:A:930:TYR:HD1	1.93	0.51
1:A:260:ASN:HB2	1:A:264:LYS:NZ	2.25	0.51
1:A:293:ARG:HB3	1:A:349:ARG:HG3	1.92	0.51
1:A:1362:ALA:HB2	1:A:1456:PHE:HB3	1.93	0.51
1:A:484:THR:HG23	2:N:10:C:C5	2.46	0.51
1:A:693:GLU:HA	1:A:694:ASP:HB3	1.92	0.51
1:A:651:ARG:NH2	1:A:738:THR:OG1	2.44	0.51
1:A:686:ALA:HA	1:A:804:TYR:CZ	2.46	0.51
1:A:916:PHE:H	1:A:933:SER:HB2	1.74	0.51
1:A:880:PRO:HB3	1:A:1346:ARG:CG	2.36	0.51
1:A:1485:LEU:O	1:A:1494:GLY:HA3	2.11	0.51
1:A:304:LYS:O	1:A:312:HIS:HD2	1.94	0.51
1:A:692:MET:HB3	1:A:696:VAL:CG1	2.41	0.51
3:J:13:U:H2'	3:J:14:U:C6	2.46	0.51
1:A:693:GLU:OE1	1:A:708:CYS:HA	2.12	0.50
1:A:866:TYR:HB2	1:A:1547:LEU:HD21	1.93	0.50
1:A:320:LYS:HG2	1:A:326:SER:CB	2.40	0.50

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:900:ILE:CG2	1:A:1497:GLU:HB3	2.41	0.50
1:A:917:ARG:HG3	1:A:918:PRO:CD	2.40	0.50
1:A:430:LEU:HB2	1:A:519:MET:HB3	1.94	0.50
1:A:458:TYR:OH	1:A:619:ASN:OD1	2.29	0.50
1:A:796:LEU:HD13	1:A:822:ILE:HG21	1.93	0.50
1:A:830:SER:HA	1:A:833:MET:HE3	1.92	0.50
1:A:1328:TYR:CB	1:A:1331:LYS:HB2	2.39	0.50
1:A:415:PRO:O	1:A:567:LYS:HA	2.11	0.50
1:A:564:SER:HB3	2:N:17:C:OP1	2.10	0.50
1:A:874:VAL:HG21	1:A:1309:LEU:HD23	1.93	0.50
1:A:227:ARG:NH1	1:A:227:ARG:HB2	2.26	0.50
1:A:965:CYS:SG	1:A:1311:PRO:HA	2.51	0.50
1:A:305:ASP:HB3	1:A:311:ASP:O	2.12	0.50
1:A:728:LEU:HD23	1:A:774:GLY:HA3	1.92	0.50
1:A:823:LYS:O	1:A:823:LYS:HG3	2.12	0.50
1:A:1416:VAL:HB	1:A:1597:TRP:CZ2	2.46	0.50
1:A:530:PHE:CZ	1:A:532:LEU:HB2	2.47	0.50
1:A:578:GLU:CG	1:A:610:LEU:HA	2.42	0.50
1:A:417:PHE:CZ	1:A:430:LEU:HD12	2.47	0.50
1:A:497:GLU:OE2	1:A:661:TYR:N	2.43	0.50
1:A:1325:LEU:HD22	1:A:1332:ARG:NE	2.27	0.50
1:A:1583:GLU:HG2	1:A:1584:PHE:HD1	1.74	0.50
1:A:92:THR:HG23	1:A:92:THR:O	2.10	0.50
1:A:1385:PRO:HB2	1:A:1444:THR:CG2	2.41	0.50
1:A:1394:PRO:HD3	2:N:28:C:HO2'	1.76	0.50
1:A:341:GLU:HG2	1:A:342:LEU:N	2.27	0.49
1:A:864:PRO:HA	1:A:1559:VAL:HG12	1.93	0.49
1:A:125:PHE:HA	1:A:217:LEU:HD22	1.92	0.49
1:A:1521:ASN:O	1:A:1525:LYS:HG2	2.13	0.49
2:N:10:C:H2'	2:N:10:C:O2	2.10	0.49
1:A:19:LYS:HD3	1:A:32:GLU:OE2	2.12	0.49
1:A:589:ASN:O	1:A:593:LYS:HE2	2.12	0.49
1:A:1394:PRO:CD	2:N:28:C:O2'	2.60	0.49
1:A:210:VAL:O	1:A:215:ARG:NH1	2.45	0.49
1:A:409:GLU:OE1	1:A:574:ASN:HB2	2.13	0.49
1:A:717:GLU:O	1:A:717:GLU:HG2	2.13	0.49
1:A:967:ARG:NH2	2:N:23:U:O3'	2.45	0.49
1:A:1391:LEU:HD13	2:N:28:C:C5	2.48	0.49
1:A:1458:ILE:CD1	1:A:1475:LEU:HD11	2.36	0.49
1:A:692:MET:HA	1:A:698:LEU:HA	1.94	0.49
1:A:977:TRP:CD1	1:A:1402:GLY:HA2	2.48	0.49

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:165:LYS:HD2	1:A:190:TYR:OH	2.12	0.49
1:A:511:VAL:HG23	2:N:21:C:H1'	1.95	0.49
1:A:513:GLU:HB2	1:A:1330:GLU:HG2	1.93	0.49
1:A:562:ALA:N	2:N:16:A:OP2	2.31	0.49
1:A:28:LYS:HA	1:A:99:LEU:HD12	1.95	0.49
1:A:458:TYR:CE2	1:A:547:THR:HG21	2.47	0.49
1:A:576:LYS:HB3	1:A:610:LEU:HB3	1.95	0.49
1:A:1587:GLU:OE1	1:A:1587:GLU:N	2.45	0.49
1:A:230:GLY:HA2	2:N:10:C:OP1	2.13	0.49
1:A:340:LYS:HD2	1:A:340:LYS:O	2.12	0.49
1:A:486:MET:HB2	1:A:531:GLN:HB3	1.95	0.49
1:A:589:ASN:O	1:A:593:LYS:HG2	2.13	0.49
1:A:904:PRO:HA	1:A:1448:LEU:O	2.12	0.49
1:A:971:GLU:O	1:A:1301:ILE:HG22	2.13	0.49
1:A:1395:ARG:HB2	2:N:30:A:H4'	1.95	0.49
1:A:1547:LEU:CD2	1:A:1596:PRO:HB3	2.43	0.49
1:A:1552:GLU:O	1:A:1555:GLN:HG2	2.12	0.49
1:A:28:LYS:CE	1:A:388:ARG:HH11	2.26	0.48
1:A:127:GLU:HA	1:A:147:ARG:HH11	1.78	0.48
1:A:158:LYS:N	1:A:159:PRO:HD3	2.28	0.48
1:A:295:SER:HG	1:A:298:LEU:HD12	1.75	0.48
1:A:847:LYS:NZ	1:A:1499:ASP:OD1	2.38	0.48
1:A:7:ILE:CG2	1:A:204:ILE:HD12	2.35	0.48
1:A:1325:LEU:HD22	1:A:1332:ARG:HE	1.78	0.48
1:A:92:THR:H	2:N:5:U:H3	1.60	0.48
1:A:329:ILE:O	1:A:333:LEU:HG	2.12	0.48
1:A:695:GLY:HA2	1:A:696:VAL:CG2	2.43	0.48
1:A:960:THR:HG23	1:A:1544:LEU:HD22	1.95	0.48
1:A:406:VAL:HB	1:A:532:LEU:HB3	1.95	0.48
1:A:555:GLY:HA2	1:A:571:ARG:HB2	1.94	0.48
1:A:560:SER:OG	1:A:568:GLY:HA3	2.13	0.48
1:A:1341:LEU:CD2	1:A:1345:CYS:HB3	2.43	0.48
1:A:1586:LYS:HB3	1:A:1587:GLU:OE1	2.13	0.48
1:A:194:HIS:O	1:A:198:PRO:HB3	2.14	0.48
1:A:499:ARG:HD2	1:A:521:VAL:HG21	1.95	0.48
1:A:272:ILE:CD1	1:A:332:ILE:HD11	2.44	0.48
1:A:962:THR:HG22	1:A:1470:LEU:HD13	1.94	0.48
2:N:21:C:H2'	2:N:22:U:C6	2.49	0.48
1:A:267:GLU:O	1:A:270:ILE:HG12	2.13	0.48
1:A:429:ASP:HB3	3:J:22:C:N4	2.29	0.48
1:A:971:GLU:HB2	1:A:1302:GLY:HA3	1.96	0.48

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:146:PHE:CB	1:A:149:HIS:HB2	2.44	0.47
1:A:415:PRO:HD3	1:A:524:GLU:HG2	1.95	0.47
1:A:830:SER:HA	1:A:833:MET:CE	2.43	0.47
1:A:959:GLU:HG2	1:A:1344:ALA:CB	2.44	0.47
1:A:639:ILE:HD11	1:A:655:VAL:HG12	1.97	0.47
1:A:690:ILE:HD11	1:A:798:ASP:OD2	2.15	0.47
1:A:1484:LYS:HB3	1:A:1489:LYS:HD3	1.95	0.47
1:A:875:GLU:O	1:A:1343:PRO:HD3	2.15	0.47
1:A:896:ARG:HB2	1:A:1504:ARG:NH2	2.30	0.47
1:A:945:ILE:HB	1:A:1362:ALA:HB3	1.95	0.47
1:A:1564:LEU:HD22	2:N:31:A:N6	2.29	0.47
1:A:30:ASN:HB3	1:A:33:PHE:HB3	1.95	0.47
1:A:891:LEU:HD13	1:A:1468:LEU:HD23	1.97	0.47
1:A:28:LYS:NZ	1:A:388:ARG:HD2	2.29	0.47
1:A:421:ILE:HG23	1:A:431:GLN:NE2	2.30	0.47
1:A:768:ARG:HB2	1:A:940:HIS:CD2	2.50	0.47
1:A:844:VAL:HB	1:A:1516:ASN:OD1	2.15	0.47
1:A:864:PRO:HG2	1:A:1561:TYR:CG	2.50	0.47
1:A:1404:ASP:HB3	1:A:1407:PHE:CD2	2.49	0.47
1:A:1535:ARG:O	1:A:1535:ARG:HG3	2.15	0.47
1:A:41:ARG:HH11	1:A:57:THR:HG21	1.80	0.47
1:A:472:CYS:HB3	1:A:477:CYS:HB3	1.85	0.47
1:A:444:ARG:CB	1:A:485:VAL:HG23	2.37	0.46
1:A:463:CYS:N	1:A:474:CYS:SG	2.88	0.46
1:A:504:ILE:HG12	2:N:19:U:H2'	1.96	0.46
1:A:645:ARG:NH1	1:A:661:TYR:OH	2.40	0.46
1:A:98:LEU:HD23	1:A:388:ARG:HH22	1.80	0.46
1:A:127:GLU:HB3	1:A:147:ARG:HD3	1.97	0.46
1:A:916:PHE:H	1:A:933:SER:CB	2.29	0.46
1:A:688:ALA:CB	1:A:710:LEU:HD11	2.35	0.46
1:A:845:PRO:HD3	1:A:1516:ASN:O	2.14	0.46
1:A:65:VAL:HG13	1:A:221:SER:CB	2.45	0.46
1:A:492:TYR:CE1	1:A:523:PRO:HG3	2.50	0.46
1:A:47:LYS:HG3	1:A:48:ASP:N	2.28	0.46
1:A:171:ARG:O	1:A:188:LYS:HA	2.16	0.46
1:A:639:ILE:HB	1:A:761:PRO:HB3	1.97	0.46
1:A:863:TYR:HE2	1:A:865:HIS:CE1	2.33	0.46
1:A:95:LYS:NZ	1:A:97:ARG:HB3	2.31	0.46
1:A:295:SER:CB	1:A:298:LEU:HD12	2.46	0.46
1:A:716:SER:OG	1:A:717:GLU:N	2.48	0.46
1:A:1375:LYS:HG3	1:A:1376:ASN:OD1	2.16	0.46

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:737:VAL:O	1:A:761:PRO:HD2	2.16	0.46
1:A:270:ILE:HG13	1:A:271:SER:N	2.30	0.46
1:A:320:LYS:C	1:A:321:LYS:HG3	2.35	0.46
1:A:577:TYR:CD1	1:A:614:LEU:HA	2.51	0.46
1:A:809:LYS:O	1:A:814:TYR:HB2	2.16	0.46
1:A:16:ARG:HA	1:A:190:TYR:O	2.16	0.46
1:A:1393:ARG:HB3	3:J:12:G:N2	2.30	0.46
1:A:1464:LYS:HB2	1:A:1467:GLU:HG3	1.98	0.46
1:A:757:PHE:HB3	3:J:16:A:C5	2.51	0.45
1:A:805:PRO:HA	1:A:815:GLY:O	2.15	0.45
1:A:1477:LEU:HD22	1:A:1548:LEU:HD13	1.98	0.45
1:A:547:THR:HG22	1:A:617:PRO:HB3	1.97	0.45
1:A:824:GLY:O	1:A:825:ASP:C	2.55	0.45
1:A:1347:LEU:HD11	1:A:1463:LEU:HD21	1.98	0.45
1:A:327:VAL:CG2	1:A:331:GLN:HB2	2.46	0.45
1:A:756:LYS:HD3	1:A:756:LYS:C	2.37	0.45
1:A:13:GLU:OE2	2:N:10:C:N4	2.47	0.45
1:A:497:GLU:HG2	1:A:661:TYR:CD2	2.51	0.45
1:A:513:GLU:OE1	1:A:1330:GLU:HA	2.17	0.45
1:A:656:VAL:HG22	1:A:657:THR:N	2.31	0.45
1:A:696:VAL:HG12	1:A:696:VAL:O	2.16	0.45
1:A:549:LEU:HB3	1:A:614:LEU:CD2	2.45	0.45
1:A:43:HIS:HD2	1:A:53:ARG:NH1	2.15	0.45
1:A:123:CYS:SG	1:A:126:CYS:CB	3.03	0.45
1:A:171:ARG:HD2	1:A:433:LEU:HD13	1.99	0.45
1:A:276:ASN:O	1:A:278:LYS:HG2	2.16	0.45
2:N:31:A:H2'	2:N:32:G:C8	2.51	0.45
1:A:693:GLU:HA	1:A:694:ASP:CB	2.47	0.45
1:A:99:LEU:HA	1:A:100:GLN:HA	1.63	0.45
1:A:152:ASN:HD22	2:N:1:U:H1'	1.82	0.45
1:A:267:GLU:HA	1:A:270:ILE:HG12	1.99	0.45
1:A:786:GLU:HG2	1:A:787:GLU:N	2.32	0.45
1:A:874:VAL:HG22	1:A:963:ASN:O	2.16	0.45
1:A:1483:HIS:O	1:A:1495:SER:HA	2.17	0.45
1:A:558:PHE:HA	1:A:568:GLY:O	2.17	0.44
1:A:1472:ILE:HG23	1:A:1500:VAL:HG21	1.99	0.44
1:A:132:SER:CB	1:A:135:ASP:HB2	2.47	0.44
1:A:272:ILE:HD12	1:A:332:ILE:HD11	1.99	0.44
1:A:402:LYS:HG3	1:A:539:ASP:HA	1.99	0.44
1:A:895:ILE:HG22	1:A:897:CYS:SG	2.57	0.44
1:A:970:ASP:OD1	1:A:970:ASP:O	2.35	0.44

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:23:SER:HA	1:A:26:ARG:HD2	1.99	0.44
1:A:1299:ARG:CG	1:A:1303:LYS:HG3	2.42	0.44
1:A:1354:LYS:HG3	2:N:22:U:H5''	1.98	0.44
2:N:14:A:HO2'	2:N:15:C:P	2.35	0.44
1:A:786:GLU:OE1	1:A:786:GLU:N	2.31	0.44
1:A:887:HIS:HB2	1:A:890:ARG:HG3	1.99	0.44
1:A:1458:ILE:CD1	1:A:1475:LEU:HD21	2.48	0.44
1:A:899:LEU:N	1:A:1454:PHE:O	2.49	0.44
1:A:1585:LYS:O	1:A:1589:ARG:NH2	2.51	0.44
1:A:260:ASN:HD22	1:A:264:LYS:NZ	2.16	0.44
1:A:501:ARG:HB2	1:A:517:PHE:CZ	2.52	0.44
1:A:614:LEU:HD12	1:A:615:PRO:CD	2.34	0.44
1:A:619:ASN:OD1	1:A:619:ASN:O	2.36	0.44
1:A:634:MET:HE1	1:A:638:PHE:HB2	1.99	0.44
1:A:1534:PHE:HB2	1:A:1538:LEU:HD21	2.00	0.44
1:A:125:PHE:CA	1:A:217:LEU:HD22	2.48	0.44
1:A:454:ASP:HB3	1:A:548:VAL:HG13	2.00	0.44
1:A:780:ARG:O	1:A:784:GLU:HG2	2.18	0.44
1:A:453:ARG:HD3	2:N:13:A:N6	2.32	0.44
1:A:877:GLU:CG	1:A:878:GLU:CA	2.95	0.44
1:A:1417:HIS:ND1	1:A:1495:SER:OG	2.37	0.44
1:A:210:VAL:HB	1:A:215:ARG:NH1	2.33	0.44
1:A:15:PHE:CZ	1:A:192:VAL:HB	2.53	0.43
1:A:349:ARG:HG2	1:A:353:GLU:OE2	2.18	0.43
1:A:430:LEU:O	1:A:520:GLU:N	2.37	0.43
1:A:472:CYS:C	1:A:477:CYS:HB3	2.39	0.43
1:A:1398:TRP:CG	2:N:30:A:H5'	2.53	0.43
1:A:42:TRP:HZ3	1:A:167:ILE:HD13	1.82	0.43
1:A:756:LYS:HE3	2:N:26:A:N6	2.33	0.43
1:A:957:VAL:O	1:A:960:THR:HG22	2.18	0.43
1:A:827:LYS:HE2	1:A:831:ARG:CD	2.48	0.43
1:A:1364:LEU:CD2	1:A:1368:PRO:HB3	2.48	0.43
2:N:31:A:C2	2:N:32:G:C5	3.06	0.43
1:A:232:LEU:HD21	1:A:484:THR:HG21	1.99	0.43
1:A:292:LEU:HA	1:A:295:SER:CB	2.49	0.43
1:A:1505:LEU:HD11	1:A:1522:TRP:CZ2	2.54	0.43
2:N:18:G:C3'	2:N:19:U:H5''	2.47	0.43
1:A:41:ARG:HD2	1:A:57:THR:HG23	1.98	0.43
1:A:293:ARG:NH2	1:A:496:PRO:O	2.51	0.43
1:A:304:LYS:HG2	1:A:305:ASP:H	1.84	0.43
1:A:305:ASP:HB3	1:A:311:ASP:C	2.39	0.43

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:446:ALA:O	1:A:450:ILE:HG12	2.18	0.43
1:A:604:GLU:O	1:A:608:LYS:HG3	2.19	0.43
1:A:1415:TYR:OH	2:N:28:C:H5"	2.19	0.43
1:A:1565:ARG:NH1	3:J:9:U:H5	2.17	0.43
3:J:8:C:C4'	3:J:9:U:OP1	2.66	0.43
1:A:327:VAL:HG22	1:A:331:GLN:HB2	2.00	0.43
1:A:433:LEU:HD23	1:A:443:PRO:HG3	2.00	0.43
1:A:73:LEU:O	1:A:77:ASP:N	2.51	0.43
1:A:339:THR:OG1	1:A:342:LEU:HG	2.18	0.43
1:A:877:GLU:CG	1:A:878:GLU:HA	2.48	0.43
1:A:934:TYR:HE2	1:A:1443:ARG:HD2	1.84	0.43
1:A:67:ARG:O	1:A:71:ASN:ND2	2.51	0.43
1:A:400:VAL:HA	1:A:583:SER:OG	2.18	0.43
1:A:433:LEU:HD21	1:A:441:ARG:HD3	1.99	0.43
1:A:747:PHE:CD1	1:A:1409:VAL:HG13	2.54	0.43
1:A:838:ASP:OD1	1:A:838:ASP:N	2.50	0.43
1:A:934:TYR:CE2	1:A:1443:ARG:HD2	2.54	0.43
1:A:943:ILE:HD11	1:A:1370:TRP:CH2	2.54	0.43
1:A:1579:LEU:HD21	1:A:1600:TRP:HB2	2.00	0.43
2:N:34:U:H3	3:J:7:G:H1	1.67	0.43
1:A:451:LEU:HG	1:A:552:TRP:CH2	2.54	0.43
3:J:16:A:H2'	3:J:17:A:C8	2.54	0.43
1:A:501:ARG:NE	1:A:677:GLU:HG2	2.33	0.42
1:A:842:VAL:HG11	1:A:1517:SER:HB3	2.00	0.42
1:A:914:ASP:OD1	1:A:917:ARG:HB2	2.20	0.42
1:A:7:ILE:HA	1:A:236:ARG:O	2.19	0.42
1:A:444:ARG:HB2	1:A:485:VAL:CG2	2.37	0.42
1:A:709:LEU:HD12	1:A:788:TYR:HE1	1.83	0.42
1:A:870:PRO:HG2	1:A:1309:LEU:HD11	2.02	0.42
1:A:1564:LEU:HG	2:N:30:A:C6	2.55	0.42
1:A:803:LEU:HD21	1:A:886:PHE:HZ	1.78	0.42
1:A:1458:ILE:HD11	1:A:1475:LEU:HD21	2.01	0.42
1:A:178:PHE:CZ	1:A:457:THR:HG22	2.54	0.42
1:A:303:PRO:HD2	1:A:315:TRP:CD1	2.55	0.42
1:A:556:GLN:HE22	1:A:623:PRO:HB2	1.84	0.42
1:A:661:TYR:HB3	1:A:668:ALA:HB1	2.01	0.42
1:A:674:TYR:N	1:A:728:LEU:O	2.51	0.42
1:A:730:PHE:CE2	1:A:772:LEU:HD13	2.54	0.42
1:A:303:PRO:HG3	1:A:647:ALA:O	2.19	0.42
1:A:314:LEU:O	1:A:317:ILE:HG13	2.19	0.42
1:A:561:GLY:CA	2:N:15:C:H5"	2.49	0.42

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:932:LYS:HD2	1:A:1443:ARG:CZ	2.50	0.42
1:A:1393:ARG:HB3	3:J:12:G:H21	1.84	0.42
1:A:679:PHE:O	1:A:683:ILE:HG12	2.20	0.42
1:A:28:LYS:HA	1:A:99:LEU:CD1	2.50	0.42
1:A:636:SER:HB2	1:A:813:GLY:O	2.20	0.42
1:A:1590:GLN:HA	1:A:1590:GLN:OE1	2.19	0.42
1:A:91:ASP:OD1	1:A:391:LYS:HD3	2.19	0.42
1:A:129:LEU:HD23	1:A:129:LEU:HA	1.89	0.42
1:A:1386:VAL:O	1:A:1386:VAL:HG13	2.19	0.42
1:A:167:ILE:HG13	1:A:168:GLY:N	2.34	0.42
1:A:314:LEU:HA	1:A:317:ILE:HD11	2.02	0.42
1:A:845:PRO:HD2	1:A:1519:ILE:HD12	2.02	0.42
1:A:1546:LYS:HD2	1:A:1596:PRO:HG2	2.01	0.42
1:A:128:LEU:HA	1:A:148:ILE:HD12	2.01	0.42
1:A:404:THR:HG21	1:A:541:LEU:HD11	1.99	0.42
1:A:719:GLU:O	1:A:720:ALA:C	2.57	0.42
1:A:347:LYS:HD3	1:A:347:LYS:HA	1.79	0.41
3:J:22:C:HO2'	3:J:23:G:P	2.43	0.41
1:A:1393:ARG:HB2	1:A:1394:PRO:HD2	2.02	0.41
1:A:1489:LYS:HB2	2:N:28:C:OP1	2.20	0.41
1:A:226:ASP:HB2	1:A:598:ARG:CD	2.50	0.41
1:A:456:GLN:HG3	1:A:476:THR:HG21	2.03	0.41
1:A:1418:HIS:CE1	1:A:1420:ALA:HB3	2.56	0.41
1:A:1466:TRP:CB	1:A:1526:GLY:HA2	2.50	0.41
1:A:1472:ILE:O	1:A:1476:GLN:HG2	2.21	0.41
1:A:95:LYS:HZ3	1:A:97:ARG:HB3	1.85	0.41
1:A:877:GLU:CG	1:A:878:GLU:CB	2.88	0.41
1:A:944:MET:HA	1:A:1362:ALA:O	2.21	0.41
1:A:8:SER:HA	1:A:200:PHE:O	2.21	0.41
1:A:646:ALA:HB1	1:A:653:THR:O	2.21	0.41
1:A:401:LEU:HD23	1:A:582:LEU:HD12	2.03	0.41
1:A:504:ILE:CG1	2:N:19:U:H2'	2.50	0.41
1:A:556:GLN:O	1:A:556:GLN:HG2	2.20	0.41
1:A:844:VAL:HG21	1:A:1500:VAL:O	2.20	0.41
1:A:845:PRO:HG2	1:A:1519:ILE:HB	2.03	0.41
1:A:907:VAL:HB	1:A:936:PHE:CZ	2.55	0.41
1:A:1364:LEU:HD21	1:A:1368:PRO:HB3	2.02	0.41
1:A:115:CYS:HA	1:A:116:PRO:HD3	1.90	0.41
1:A:323:ASP:HB3	1:A:326:SER:OG	2.21	0.41
1:A:679:PHE:CE1	1:A:683:ILE:HD11	2.56	0.41
1:A:924:ARG:O	1:A:927:LYS:HG3	2.21	0.41

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:1401:PRO:HG2	1:A:1407:PHE:CE1	2.56	0.41
3:J:6:A:O2'	3:J:7:G:P	2.79	0.41
1:A:411:VAL:HG23	1:A:573:GLU:HG3	2.01	0.41
1:A:437:ASP:O	1:A:437:ASP:OD1	2.39	0.41
1:A:1332:ARG:O	1:A:1336:ARG:HG3	2.21	0.41
1:A:60:LEU:HG	1:A:228:LEU:HD11	2.03	0.41
1:A:68:SER:HB2	1:A:221:SER:OG	2.20	0.41
1:A:302:LEU:HD23	1:A:302:LEU:HA	1.94	0.41
1:A:503:ARG:HB3	1:A:515:ALA:HB1	2.02	0.41
1:A:614:LEU:CG	1:A:615:PRO:HD2	2.51	0.41
1:A:816:GLN:HE22	1:A:1358:ARG:HH21	1.68	0.41
1:A:1337:HIS:ND1	1:A:1338:PRO:HD2	2.36	0.41
1:A:1545:LYS:O	1:A:1549:TRP:N	2.54	0.41
1:A:128:LEU:HD22	1:A:217:LEU:CD2	2.51	0.41
1:A:196:ARG:HB2	1:A:197:PHE:CD1	2.56	0.41
1:A:713:ILE:O	1:A:723:ILE:HG22	2.21	0.41
1:A:845:PRO:CG	1:A:1520:PRO:HD3	2.49	0.41
1:A:1488:ALA:O	1:A:1493:PHE:HB2	2.21	0.41
1:A:1546:LYS:O	1:A:1549:TRP:HB3	2.21	0.41
1:A:25:ARG:HB3	1:A:30:ASN:ND2	2.35	0.40
1:A:174:ASN:OD1	2:N:13:A:H3'	2.21	0.40
1:A:400:VAL:HG23	1:A:401:LEU:H	1.86	0.40
1:A:542:PRO:HD2	1:A:545:LEU:HD23	2.02	0.40
1:A:1301:ILE:O	1:A:1304:ARG:HB2	2.22	0.40
1:A:1436:ILE:HG22	1:A:1437:GLU:N	2.36	0.40
1:A:502:THR:HG23	1:A:516:LEU:HD13	2.03	0.40
1:A:862:TYR:O	1:A:1559:VAL:HA	2.21	0.40
1:A:37:GLN:HA	1:A:37:GLN:OE1	2.22	0.40
1:A:53:ARG:HH21	1:A:158:LYS:HD2	1.87	0.40
1:A:234:VAL:O	1:A:234:VAL:HG23	2.21	0.40
1:A:349:ARG:HD2	1:A:495:PRO:HG3	2.04	0.40
1:A:458:TYR:O	1:A:621:ARG:NH1	2.54	0.40
1:A:595:TRP:O	1:A:598:ARG:HG3	2.21	0.40
1:A:634:MET:HE3	1:A:638:PHE:HB2	2.02	0.40
1:A:862:TYR:HB2	1:A:1559:VAL:HG22	2.04	0.40
1:A:1434:LYS:HB3	1:A:1434:LYS:HE3	1.92	0.40
1:A:1448:LEU:HB3	1:A:1452:ASN:ND2	2.37	0.40
3:J:8:C:C1'	3:J:9:U:OP1	2.69	0.40
1:A:292:LEU:CA	1:A:295:SER:HB2	2.51	0.40
1:A:669:LYS:HA	1:A:670:PRO:HD3	1.93	0.40
1:A:816:GLN:OE1	1:A:1358:ARG:NE	2.47	0.40

Continued on next page...

Continued from previous page...

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:1337:HIS:CG	1:A:1338:PRO:HD2	2.56	0.40
3:J:9:U:H4'	3:J:10:U:O5'	2.20	0.40
1:A:448:ARG:CZ	1:A:480:MET:HE3	2.51	0.40
1:A:707:GLU:O	1:A:707:GLU:HG3	2.20	0.40

There are no symmetry-related clashes.

5.3 Torsion angles [i](#)

5.3.1 Protein backbone [i](#)

In the following table, the Percentiles column shows the percent Ramachandran outliers of the chain as a percentile score with respect to all PDB entries followed by that with respect to all EM entries.

The Analysed column shows the number of residues for which the backbone conformation was analysed, and the total number of residues.

Mol	Chain	Analysed	Favoured	Allowed	Outliers	Percentiles
1	A	1241/1253 (99%)	1169 (94%)	72 (6%)	0	100 100

There are no Ramachandran outliers to report.

5.3.2 Protein sidechains [i](#)

In the following table, the Percentiles column shows the percent sidechain outliers of the chain as a percentile score with respect to all PDB entries followed by that with respect to all EM entries.

The Analysed column shows the number of residues for which the sidechain conformation was analysed, and the total number of residues.

Mol	Chain	Analysed	Rotameric	Outliers	Percentiles
1	A	1075/1079 (100%)	1073 (100%)	2 (0%)	93 98

All (2) residues with a non-rotameric sidechain are listed below:

Mol	Chain	Res	Type
1	A	321	LYS
1	A	640	ASN

Sometimes sidechains can be flipped to improve hydrogen bonding and reduce clashes. All (2) such sidechains are listed below:

Mol	Chain	Res	Type
1	A	556	GLN
1	A	712	GLN

5.3.3 RNA

Mol	Chain	Analysed	Backbone Outliers	Pucker Outliers
2	N	33/34 (97%)	12 (36%)	0
3	J	18/18 (100%)	9 (50%)	4 (22%)
All	All	51/52 (98%)	21 (41%)	4 (7%)

All (21) RNA backbone outliers are listed below:

Mol	Chain	Res	Type
2	N	2	U
2	N	4	A
2	N	11	G
2	N	12	G
2	N	13	A
2	N	14	A
2	N	18	G
2	N	19	U
2	N	24	U
2	N	30	A
2	N	31	A
2	N	32	G
3	J	7	G
3	J	8	C
3	J	9	U
3	J	10	U
3	J	12	G
3	J	16	A
3	J	19	G
3	J	22	C
3	J	23	G

All (4) RNA pucker outliers are listed below:

Mol	Chain	Res	Type
3	J	6	A

Continued on next page...

Continued from previous page...

Mol	Chain	Res	Type
3	J	8	C
3	J	9	U
3	J	21	A

5.4 Non-standard residues in protein, DNA, RNA chains [i](#)

There are no non-standard protein/DNA/RNA residues in this entry.

5.5 Carbohydrates [i](#)

There are no monosaccharides in this entry.

5.6 Ligand geometry [i](#)

There are no ligands in this entry.

5.7 Other polymers [i](#)

There are no such residues in this entry.

5.8 Polymer linkage issues [i](#)

The following chains have linkage breaks:

Mol	Chain	Number of breaks
1	A	3

All chain breaks are listed below:

Model	Chain	Residue-1	Atom-1	Residue-2	Atom-2	Distance (Å)
1	A	238:ASP	C	257:PRO	N	44.03
1	A	141:LYS	C	142:LYS	N	10.82
1	A	978:ARG	C	1296:VAL	N	5.59


6 Map visualisation [i](#)

This section contains visualisations of the EMDB entry EMD-27138. These allow visual inspection of the internal detail of the map and identification of artifacts.


Images derived from a raw map, generated by summing the deposited half-maps, are presented below the corresponding image components of the primary map to allow further visual inspection and comparison with those of the primary map.

6.1 Orthogonal projections [i](#)

6.1.1 Primary map




6.1.2 Raw map




The images above show the map projected in three orthogonal directions.

6.2 Central slices


6.2.1 Primary map



X Index: 150




Y Index: 150




Z Index: 150


6.2.2 Raw map



X Index: 150



Y Index: 150




Z Index: 150


The images above show central slices of the map in three orthogonal directions.

6.3 Largest variance slices ⓘ


6.3.1 Primary map



X Index: 161




Y Index: 162




Z Index: 152


6.3.2 Raw map



X Index: 161



Y Index: 166



Z Index: 153

The images above show the largest variance slices of the map in three orthogonal directions.

6.4 Orthogonal surface views

6.4.1 Primary map



The images above show the 3D surface view of the map at the recommended contour level 0.0146. These images, in conjunction with the slice images, may facilitate assessment of whether an appropriate contour level has been provided.

6.4.2 Raw map



These images show the 3D surface of the raw map. The raw map's contour level was selected so that its surface encloses the same volume as the primary map does at its recommended contour level.


6.5 Mask visualisation

This section was not generated. No masks/segmentation were deposited.

7 Map analysis i


This section contains the results of statistical analysis of the map.

7.1 Map-value distribution i



The map-value distribution is plotted in 128 intervals along the x-axis. The y-axis is logarithmic. A spike in this graph at zero usually indicates that the volume has been masked.


7.2 Volume estimate (i)



The volume at the recommended contour level is 43 nm³; this corresponds to an approximate mass of 39 kDa.

The volume estimate graph shows how the enclosed volume varies with the contour level. The recommended contour level is shown as a vertical line and the intersection between the line and the curve gives the volume of the enclosed surface at the given level.

7.3 Rotationally averaged power spectrum ⓘ




*Reported resolution corresponds to spatial frequency of 0.355 Å⁻¹

8 Fourier-Shell correlation i

Fourier-Shell Correlation (FSC) is the most commonly used method to estimate the resolution of single-particle and subtomogram-averaged maps. The shape of the curve depends on the imposed symmetry, mask and whether or not the two 3D reconstructions used were processed from a common reference. The reported resolution is shown as a black line. A curve is displayed for the half-bit criterion in addition to lines showing the 0.143 gold standard cut-off and 0.5 cut-off.

8.1 FSC i



*Reported resolution corresponds to spatial frequency of 0.355 Å⁻¹

8.2 Resolution estimates ⓘ


Resolution estimate (Å)	Estimation criterion (FSC cut-off)		
	0.143	0.5	Half-bit
Reported by author	2.82	-	-
Author-provided FSC curve	-	-	-
Unmasked-calculated*	3.12	3.67	3.17

*Resolution estimate based on FSC curve calculated by comparison of deposited half-maps. The value from deposited half-maps intersecting FSC 0.143 CUT-OFF 3.12 differs from the reported value 2.82 by more than 10 %

9 Map-model fit ⓘ


This section contains information regarding the fit between EMDB map EMD-27138 and PDB model 8D1V. Per-residue inclusion information can be found in section 3 on page 4.

9.1 Map-model overlay ⓘ



The images above show the 3D surface view of the map at the recommended contour level 0.0146 at 50% transparency in yellow overlaid with a ribbon representation of the model coloured in blue. These images allow for the visual assessment of the quality of fit between the atomic model and the map.

9.2 Atom inclusion i



At the recommended contour level, 76% of all backbone atoms, 69% of all non-hydrogen atoms, are inside the map.